<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id><journal-id journal-id-type="hwp">jco</journal-id><journal-id journal-id-type="pmc">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26033801</article-id><article-id pub-id-type="pmc">4486345</article-id><article-id pub-id-type="publisher-id">00734</article-id><article-id pub-id-type="doi">10.1200/JCO.2014.60.0734</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>Pedi12</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Reports</subject><subj-group><subject>Sarcoma</subject></subj-group></subj-group></article-categories><title-group><article-title>Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial</article-title><alt-title alt-title-type="short">EURAMOS-1: MAP plus IFN-&#x003b1;-2b Versus MAP&#x02014;First Results</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bielack</surname><given-names>Stefan S.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Smeland</surname><given-names>Sigbj&#x000f8;rn</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Whelan</surname><given-names>Jeremy S.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Marina</surname><given-names>Neyssa</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Jovic</surname><given-names>Gordana</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hook</surname><given-names>Jane M.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Krailo</surname><given-names>Mark D.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gebhardt</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>P&#x000e1;pai</surname><given-names>Zsuzsanna</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Meyer</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nadel</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Randall</surname><given-names>R. Lor</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Deffenbaugh</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nagarajan</surname><given-names>Rajaram</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Brennan</surname><given-names>Bernadette</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Letson</surname><given-names>G. Douglas</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Teot</surname><given-names>Lisa A.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Goorin</surname><given-names>Allen</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Baumhoer</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kager</surname><given-names>Leo</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Werner</surname><given-names>Mathias</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lau</surname><given-names>Ching C.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sundby Hall</surname><given-names>Kirsten</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gelderblom</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Meyers</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gorlick</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Windhager</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Helmke</surname><given-names>Knut</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Mikael</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hoogerbrugge</surname><given-names>Peter M.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Schomberg</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Tunn</surname><given-names>Per-Ulf</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>K&#x000fc;hne</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>J&#x000fc;rgens</surname><given-names>Heribert</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>van den Berg</surname><given-names>Henk</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>B&#x000f6;hling</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Picton</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Renard</surname><given-names>Marleen</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Reichardt</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gerss</surname><given-names>Joachim</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Butterfass-Bahloul</surname><given-names>Trude</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hogendoorn</surname><given-names>Pancras C.W.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Seddon</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Calaminus</surname><given-names>Gabriele</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Michelagnoli</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Dhooge</surname><given-names>Catharina</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sydes</surname><given-names>Matthew R.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Bernstein</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><on-behalf-of>on behalf of the EURAMOS-1 investigators</on-behalf-of><aff id="aff1">Stefan S. Bielack, Klinikum Stuttgart&#x02013;Olgahospital, Stuttgart; Mathias Werner, Helios Klinikum Emil von Behring; Per-Ulf Tunn, Helios Klinikum Berlin-Buch, Berlin; Knut Helmke, Altonaer Kinderkrankenhaus, Hamburg; Heribert J&#x000fc;rgens, Gabriele Calaminus, Joachim Gerss, and Trude Butterfass-Bahloul, Universit&#x000e4;tsklinikum M&#x000fc;nster, M&#x000fc;nster; Peter Reichardt, Klinik f&#x000fc;r Interdisziplin&#x000e4;re Onkologie, Bad Saarow, Germany; Sigbj&#x000f8;rn Smeland and Kirsten Sundby Hall, Oslo University Hospital; Kirsten Sundby Hall, Norwegian Radium Hospital, Oslo, Norway; Jeremy S. Whelan, University College London Hospitals; Gordana Jovic, Jane M. Hook, and Matthew R. Sydes, University College London; Beatrice Seddon and Maria Michelagnoli, University College Hospital, London; Bernadette Brennan, Christie Hospital and Royal Manchester Children's Hospital, Manchester; Susan Picton, Leeds University Hospital, Leeds, United Kingdom; Neyssa Marina, Stanford University Medical Center; Claudia Deffenbaugh, Lucille Salter Packard Children's Hospital, Palo Alto; Mark D. Krailo, Children's Oncology Group, Arcadia, CA; Mark Gebhardt and Allen Goorin, Dana-Farber Cancer Institute; Mark Gebhardt and Lisa A. Teot, Children's Hospital Boston, Boston, MA; Zsuzsanna P&#x000e1;pai, National Medical Center, Budapest, Hungary; James Meyer, Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA; Helen Nadel, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia; Mark Bernstein, Dalhousie University, Halifax, Nova Scotia, Canada; R. Lor Randall, University of Utah, Salt Lake City, UT; Rajaram Nagarajan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; G. Douglas Letson, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL; Daniel Baumhoer, Universit&#x000e4;tsspital Basel; Thomas K&#x000fc;hne, University Children's Hospital Basel, Basel, Switzerland; Leo Kager, St Anna's Children Hospital; Reinhard Windhager, Medical University of Vienna, Vienna, Austria; Ching C. Lau, Baylor College of Medicine, Houston, TX; Hans Gelderblom and Pancras C.W. Hogendoorn, Leiden University Medical Center, Leiden; Peter M. Hoogerbrugge, Radbound University Nijmegen Medical Centre, Nijmegen; Henk van den Berg, Emma Children's Hospital&#x02013;Academic Medical Centre, Amsterdam, the Netherlands; Paul Meyers and Carol Morris, Memorial Sloan Kettering Cancer Center, New York; Richard Gorlick, Montefiore Medical Center, Bronx, NY; Mikael Eriksson, Skane University Hospital, Lund, Sweden; Paula Schomberg, Mayo Clinic, Rochester, MN; Tom B&#x000f6;hling, University of Helsinki and Hospital District of Helsinki and Uusimaa Laboratoriot, Helsinki, Finland; Marleen Renard, University Hospital Leuven, Leuven; and Catharina Dhooge, University Hospital Ghent, Ghent, Belgium.</aff></contrib-group><author-notes><fn fn-type="equal"><p>M.R.S. and M.B. contributed equally to this work.</p></fn><corresp id="cor1">Corresponding author: Matthew R. Sydes, MSc, MRC Clinical Trials Unit, University College London, Aviation House (5th floor), 125 Kingsway, London, United Kingdom, WC2B 6NH; e-mail: <email>m.sydes@ucl.ac.uk</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>8</day><month>6</month><year>2015</year></pub-date><volume>33</volume><issue>20</issue><fpage>2279</fpage><lpage>2287</lpage><permissions><license license-type="open-access"><license-p>&#x000a9; 2015 American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 3.0 License: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zlj02015002279.pdf"/><abstract><sec><title>Purpose</title><p>EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-&#x003b1;-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.</p></sec><sec><title>Patients and Methods</title><p>At diagnosis, patients age &#x02264; 40 years with resectable high-grade osteosarcoma were registered. Eligibility after surgery for good response random assignment included &#x02265; two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopically complete surgery of primary tumor, &#x0003c; 10% viable tumor, and no disease progression. These patients were randomly assigned to four additional cycles MAP with or without IFN-&#x003b1;-2b (0.5 to 1.0 &#x003bc;g/kg per week subcutaneously, after chemotherapy until 2 years postregistration). Outcome measures were event-free survival (EFS; primary) and overall survival and toxicity (secondary).</p></sec><sec><title>Results</title><p>Good response was reported in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus IFN-&#x003b1;-2b, n = 357), with baseline characteristics balanced by arm. A total of 271 of 357 started IFN-&#x003b1;-2b; 105 stopped early, and 38 continued to receive treatment at data freeze. Refusal and toxicity were the main reasons for never starting IFN-&#x003b1;-2b and for stopping prematurely, respectively. Median IFN-&#x003b1;-2b duration, if started, was 67 weeks. A total of 133 of 268 patients who started IFN-&#x003b1;-2b and provided toxicity information reported grade &#x02265; 3 toxicity during IFN-&#x003b1;-2b treatment. With median follow-up of 44 months, 3-year EFS for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%); 174 EFS events were reported (MAP, n = 93; MAP plus IFN-&#x003b1;-2b, n = 81). Hazard ratio was 0.83 (95% CI, 0.61 to 1.12; <italic>P</italic> = .214) from an adjusted Cox model.</p></sec><sec><title>Conclusion</title><p>At the preplanned analysis time, MAP plus IFN-&#x003b1;-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-&#x003b1;-2b or stopped prematurely. Long-term follow-up for events and survival continues.</p></sec></abstract></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Osteosarcoma is the most frequent primary sarcoma of bone, primarily diagnosed in adolescents and young adults; however, it is rare overall, with only two to three affected individuals per million person-years. Most recent regimens have included several weeks of preoperative chemotherapy, followed by surgery and several months postoperative chemotherapy.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Reported outcomes have been similar internationally and have shown little improvement over previous decades.<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref></sup> Histologic response to preoperative chemotherapy is an important prognostic factor. A good histologic response is usually classified as &#x0003c; 10% viable tumor in the resected specimen. Good responders have had better 5-year survival than poor responders (75% to 80% <italic>v</italic> 45% to 55%).<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B4" ref-type="bibr">4</xref></sup></p><p>Four international osteosarcoma groups with a history of successfully conducted clinical trials<sup><xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref></sup> formed the European and American Osteosarcoma Study Group (EURAMOS)<sup><xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref></sup>: the Children's Oncology Group (COG), Cooperative Osteosarcoma Study Group (COSS), European Osteosarcoma Intergroup (EOI), and Scandinavian Sarcoma Group (SSG). The EURAMOS-1 trial established large-scale multinational cooperation in clinical trials for osteosarcoma.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> MAP (methotrexate, doxorubicin, and cisplatin) chemotherapy was accepted as standard.<sup><xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B12" ref-type="bibr">12</xref></sup> Intensified salvage chemotherapy was investigated in poor responders. On the basis of preclinical and clinical evidence,<sup><xref rid="B13" ref-type="bibr">13</xref></sup> we decided to investigate the value of maintenance treatment with interferon alfa (IFN-&#x003b1;) in good responders.</p><p>Maintenance treatment is well established in acute lymphoblastic leukemia<sup><xref rid="B14" ref-type="bibr">14</xref></sup> and is being investigated in sarcomas.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> IFN-&#x003b1; has antiproliferative, differentiation-inducing, apoptotic, and antiangiogenic properties, and its clinical activity has been demonstrated in several cancers, including as postchemotherapy maintenance.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref></sup> It has been associated with activity against osteosarcomas (some of which have expressed IFN-&#x003b1;/&#x003b2; receptor<sup><xref rid="B20" ref-type="bibr">20</xref></sup>) in vitro, in animal models, and in patients with metastatic disease.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> Most notably, single-institution treatment of 89 consecutive patients with semipurified leukocyte IFN-&#x003b1; as the only adjuvant treatment after surgery resulted in 10-year metastasis-free and sarcoma-specific survival rates of 39% and 43%, respectively.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> On the basis of this rationale, we aimed to test IFN-&#x003b1; as maintenance treatment in osteosarcoma.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> The objective of our random assignment was to examine whether addition of a pegylated formulation of interferon alfa-2b (IFN-&#x003b1;-2b) as maintenance therapy after postoperative MAP would improve outcomes, with event-free survival (EFS) as the primary outcome measure.</p></sec><sec sec-type="subjects|methods"><title>PATIENTS AND METHODS</title><sec><title>Setting</title><p>EURAMOS-1 was an open-label phase III randomized controlled trial (RCT) for patients with localized or metastatic high-grade osteosarcoma considered suitable for complete surgical resection. Eligibility for registration has been described previously.<sup><xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref></sup> Key criteria were localized or metastatic high-grade osteosarcoma of an extremity or the axial skeleton (with exception of craniofacial sites), with all disease sites potentially amenable to complete surgical resection, and age &#x02264; 40 years.</p><p>All patients received induction MAP followed by surgery of the primary. Thereafter, patients age &#x02265; 5 years who had completed two cycles of induction MAP, had undergone macroscopically complete resection of their primary tumor, had &#x0003c; 10% viable tumor on histologic response assessment, and had no evidence of disease progression were eligible for the good response random assignment. Histologic response assessment was conducted locally before random assignment and later confirmed by a trial reference pathologist. Random assignment had to be performed &#x0003c; 35 days after surgery. Patients age &#x0003c; 5 years at potential random assignment were excluded from random assignment because of reports of neurologic complications in young children receiving IFN-&#x003b1; for other diseases.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> Participants and/or their legal guardians, as appropriate, provided written informed consent to registration and random assignment. Regulatory and ethics approvals were obtained according to national requirements.</p></sec><sec><title>Trial Treatments and Procedures</title><p>Induction MAP (weeks 1 to 10) comprised two 5-week cycles of doxorubicin 75 mg/m<sup>2</sup> of body-surface area, cisplatin 120 mg/m<sup>2</sup>, and methotrexate 12 g/m<sup>2</sup>, followed by surgery of the primary in week 11. Doxorubicin and cisplatin were administered in weeks 1 and 6 and methotrexate in weeks 4, 5, 9, and 10 (<xref ref-type="fig" rid="F1">Fig 1</xref>, treatment scheme; Data Supplement). Up to two additional doses of methotrexate were permitted preoperatively if surgery had to be delayed. The protocol (Data Supplement) contained detailed guidance on mandatory tests and requirements for each treatment cycle, supportive care, and dose adjustments. If present, primary metastases were to be surgically removed in weeks 11 to 20.</p><fig id="F1" position="float"><label>Fig 1.</label><caption><p>Treatment scheme. IFN-&#x003b1;-2b, interferon alfa-2b; MA, methotrexate, doxorubicin; MAP, methotrexate, doxorubicin, and cisplatin; R, random assignment; SC, subcutaneously.</p></caption><graphic xlink:href="zlj9991052830001"/></fig><p>After histologic assessment of the resected tumor, consenting patients were randomly assigned in a one-to-one ratio to four postoperative cycles of MAP (weeks 12 to 29; cisplatin omitted in last two cycles) or to the same regimen followed by maintenance pegylated IFN-&#x003b1;-2b (<xref ref-type="fig" rid="F1">Fig 1</xref>). Treatment allocation was performed using concealed permuted blocks with three stratification factors: trial group (COG, COSS, EOI, or SSG), location of tumor (proximal femur or proximal humerus <italic>v</italic> other limb <italic>v</italic> axial skeleton), and presence of metastases (no <italic>v</italic> yes or possible). Lung metastases, detected by spiral computed tomography scanning, were considered certain if there were three or more lesions &#x02265; 5 mm in maximum diameter or a single lesion &#x02265; 1 cm. Scans of patients registering metastatic disease with fewer or smaller lesions were classified as possible metastatic disease. Patients were randomly assigned centrally through the Medical Research Council Clinical Trials Unit (COSS, EOI, and SSG) or COG.</p><p>Subcutaneous IFN-&#x003b1;-2b was planned weekly from week 30 to 104 at 0.5 &#x003bc;g/kg per week (maximum, 50 &#x003bc;g) for 4 weeks and increased to 1.0 &#x003bc;g/kg per week (maximum, 100 &#x003bc;g) thereafter if no flu-like symptoms worse than Common Toxicity Criteria for Adverse Events (version 3.0)<sup><xref rid="B23" ref-type="bibr">23</xref></sup> grade 2 or other toxicities worse than grade 1 were experienced.</p></sec><sec><title>Assessments</title><p>During MAP treatment, clinical and toxicity assessments were performed before each drug administration. During IFN-&#x003b1;-2b, patients were monitored twice per week for 8 weeks and once or twice per month thereafter. Adverse events were graded according to the Common Toxicity Criteria for Adverse Events (version 3.0)<sup><xref rid="B23" ref-type="bibr">23</xref></sup> and reported centrally as the maximum grade during pre- and postoperative chemotherapy and maximum grade per 3-month period during IFN-&#x003b1;-2b. Toxicity was assessed in each patient until trial treatment was stopped. Late toxicity throughout follow-up was collected at COSS, EOI, and SSG.</p><p>All patients were assessed for local and distant recurrence at predefined intervals by physical examination and radiography of the chest and primary site. Radiographically detected relapse was also imaged by computed tomography, magnetic resonance imaging, and/or bone scans and, if appropriate, confirmed by histology. Patients were observed regularly for &#x02265; 5 years after treatment (Data Supplement).</p></sec><sec><title>Statistical Analyses</title><p>The primary outcome measure was EFS, defined as time from random assignment until a first event (local recurrence, new metastatic disease, progression of primary metastatic disease, secondary malignancy, or death) or censoring at last contact. Secondary outcome measures included: overall survival (OS; time from random assignment until death resulting from any cause or last contact), short- and long-term toxicities, and quality of life, which will be the topic of separate analyses.</p><p>To detect absolute improvements of 10% from 70% to 80% in 3-year EFS (hazard ratio [HR], 0.63 in favor of IFN-&#x003b1;-2b) with two-sided 5% significance level and 80% power required &#x02265; 147 EFS events.<sup><xref rid="B24" ref-type="bibr">24</xref></sup> The same applied to an improvement in 5-year OS from 70% to 80%, requiring &#x02265; 147 deaths in the longer term. The initial plan to register 1,400 patients (to randomly assign 1,260 [good responders, n = 567; poor responders, n = 693]) was revised to approximately 2,000 patients because of a lower randomization rate and relatively fewer poor responders than anticipated.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> Interim data were reviewed annually by an independent data monitoring committee and could have been reported early if either <italic>P</italic> &#x02264; .001 for EFS<sup><xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref></sup> or severe IFN safety issues were identified.</p><p>A prespecified subgroup of patients with localized disease comprised those without definitive metastases at registration. To detect a 10% improvement from 75% to 85% in 3-year EFS and 5-year OS (HR, 0.56) with two-sided 5% significance and 80% power required 98 events.</p><p>The primary analysis used intention-to-treat principles. The Kaplan-Meier method was used to estimate survival functions, log-rank tests for differences between survival curves, and Cox models (adjusted for stratification factors) to estimate treatment effects, with suitability checked by tests for proportionality of hazards. All comparisons were expressed relative to control, with HR &#x0003c; 1 favoring IFN-&#x003b1;-2b. Consistency of treatment effect was examined using the interaction test (&#x003c7;<sup>2</sup> test for heterogeneity) in subgroups defined posthoc: sex, age, site of disease, location on bone, lung metastases, nonlung metastases, and histologic subtype. Median follow-up was calculated using reverse censoring on death.</p><p>In a prespecified exploratory analysis, EFS was computed from 23 weeks after starting postoperative chemotherapy, excluding patients who experienced progression before the expected start of IFN-&#x003b1;-2b. IFN-&#x003b1;-2b dose was summarized only for patients who could have completed and reported completing IFN-&#x003b1;-2b by the data freeze (patients registered before November 15, 2010). Analyses were performed using Stata software (versions 12.1 and 13.1; Stata, College Station, TX).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec sec-type="subjects"><title>Patients</title><p>Between April 2005 and June 2011, 2,260 patients were registered from &#x0003e; 300 sites in 17 European, North American, and Australasian countries. The data were frozen on February 15, 2013, because the event target was reached. A total of 1,041 patients were good responders, and 716 (69%) from 246 trial sites were randomly assigned (MAP, n = 359; MAP plus IFN-&#x003b1;-2b, n = 357; <xref ref-type="fig" rid="F2">Fig 2</xref>). COG, COSS, EOI, and SSG randomly assigned 300, 206, 161, and 49 patients, respectively. <xref ref-type="table" rid="T1">Table 1</xref> lists registration characteristics for these randomly assigned patients. Median age was 14 years (interquartile range [IQR], 11 to 16), and 421 (59%) were male; 630 (88%) had localized disease, and 86 (12%) had primary metastases; of these, 66 had lung-only, 15 had extrapulmonary-only, and five had both lung and extrapulmonary metastases.</p><fig id="F2" position="float"><label>Fig 2.</label><caption><p>CONSORT diagram. EFS, event-free survival; IFN-&#x003b1;-2b, interferon alfa-2b; MAP, methotrexate, doxorubicin, and cisplatin.</p></caption><graphic xlink:href="zlj9991052830002"/></fig><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Patient Characteristics at Registration</p></caption><alternatives><graphic xlink:href="zlj02015-5283-t01"/><table frame="box" rules="groups"><thead valign="bottom"><tr><th align="center" rowspan="2" colspan="1">Characteristic</th><th align="center" colspan="2" rowspan="1">MAP (n = 359)<hr/></th><th align="center" colspan="2" rowspan="1">MAP Plus IFN-&#x003b1;-2b (n = 357)<hr/></th><th align="center" colspan="2" rowspan="1">Total (N = 716)<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Male</td><td align="char" char="." rowspan="1" colspan="1">211</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">210</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">421</td><td align="char" char="." rowspan="1" colspan="1">59</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Female</td><td align="char" char="." rowspan="1" colspan="1">148</td><td align="char" char="." rowspan="1" colspan="1">41</td><td align="char" char="." rowspan="1" colspan="1">147</td><td align="char" char="." rowspan="1" colspan="1">41</td><td align="char" char="." rowspan="1" colspan="1">295</td><td align="char" char="." rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">Age at registration, years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x0003c; 5</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;5-9</td><td align="char" char="." rowspan="1" colspan="1">58</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">102</td><td align="char" char="." rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;10-19</td><td align="char" char="." rowspan="1" colspan="1">275</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char="." rowspan="1" colspan="1">288</td><td align="char" char="." rowspan="1" colspan="1">81</td><td align="char" char="." rowspan="1" colspan="1">563</td><td align="char" char="." rowspan="1" colspan="1">79</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;20-29</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">17</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x0003e; 30</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Median</td><td align="center" colspan="2" rowspan="1">14</td><td align="center" colspan="2" rowspan="1">14</td><td align="center" colspan="2" rowspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IQR</td><td align="center" colspan="2" rowspan="1">11-16</td><td align="center" colspan="2" rowspan="1">12-16</td><td align="center" colspan="2" rowspan="1">11-16</td></tr><tr><td align="left" rowspan="1" colspan="1">Site of tumor</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Femur</td><td align="char" char="." rowspan="1" colspan="1">179</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">191</td><td align="char" char="." rowspan="1" colspan="1">54</td><td align="char" char="." rowspan="1" colspan="1">370</td><td align="char" char="." rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Tibia</td><td align="char" char="." rowspan="1" colspan="1">113</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">102</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">215</td><td align="char" char="." rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Fibula</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Humerus</td><td align="char" char="." rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">69</td><td align="char" char="." rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Radius</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Ulna</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Scapula/clavicle</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pelvis/sacrum</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Rib</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Location of tumor</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Proximal</td><td align="char" char="." rowspan="1" colspan="1">156</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">150</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">306</td><td align="char" char="." rowspan="1" colspan="1">43</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Diaphysis</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Distal</td><td align="char" char="." rowspan="1" colspan="1">180</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">189</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">369</td><td align="char" char="." rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;NA (not long bone)</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">16</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Pathologic fracture at diagnosis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td align="char" char="." rowspan="1" colspan="1">321</td><td align="char" char="." rowspan="1" colspan="1">90</td><td align="char" char="." rowspan="1" colspan="1">308</td><td align="char" char="." rowspan="1" colspan="1">86</td><td align="char" char="." rowspan="1" colspan="1">629</td><td align="char" char="." rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td align="char" char="." rowspan="1" colspan="1">37</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">49</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">86</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Missing</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung metastases</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td align="char" char="." rowspan="1" colspan="1">295</td><td align="char" char="." rowspan="1" colspan="1">82</td><td align="char" char="." rowspan="1" colspan="1">288</td><td align="char" char="." rowspan="1" colspan="1">81</td><td align="char" char="." rowspan="1" colspan="1">583</td><td align="char" char="." rowspan="1" colspan="1">81</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Possible<xref ref-type="table-fn" rid="TF1-1">*</xref></td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">62</td><td align="char" char="." rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">36</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">71</td><td align="char" char="." rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">Other metastases</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;No</td><td align="char" char="." rowspan="1" colspan="1">343</td><td align="char" char="." rowspan="1" colspan="1">96</td><td align="char" char="." rowspan="1" colspan="1">348</td><td align="char" char="." rowspan="1" colspan="1">97</td><td align="char" char="." rowspan="1" colspan="1">691</td><td align="char" char="." rowspan="1" colspan="1">97</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Possible<xref ref-type="table-fn" rid="TF1-1">*</xref></td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Yes</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">WHO 2002 classification of osteosarcoma<sup><xref rid="B27" ref-type="bibr">27</xref></sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Conventional</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">90</td><td align="char" char="." rowspan="1" colspan="1">322</td><td align="char" char="." rowspan="1" colspan="1">92</td><td align="char" char="." rowspan="1" colspan="1">642</td><td align="char" char="." rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Telangiectatic</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Small cell</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;High-grade surface</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Other</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Missing</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">NA</td></tr></tbody></table></alternatives><table-wrap-foot><fn fn-type="abbr"><p>Abbreviations: IFN-&#x003b1;2b, interferon alfa-2b; IQR, interquartile range; MAP, methotrexate, doxorubicin, and cisplatin; NA, not applicable;</p></fn><fn fn-type="other" id="TF1-1"><label>*</label><p>Possible metastases were collected only by Cooperative Osteosarcoma Study Group, European Osteosarcoma Intergroup, and Scandinavian Sarcoma Group.</p></fn></table-wrap-foot></table-wrap><p>Median follow-up was 44 months (IQR, 28 to 58) for MAP and 44 months (IQR, 29 to 58) for MAP plus IFN-&#x003b1;-2b. Twenty patients (6%) in each arm were permanently lost to follow-up. For patients last reported as alive, 94% were seen &#x0003c; 14 months before data freeze.</p></sec><sec><title>Treatment</title><sec><title>Postoperative MAP.</title><p>Postoperative MAP was delivered similarly in both treatment arms. Median standardized postoperative dose of methotrexate was 95 g/m<sup>2</sup> (target, 96g/m<sup>2</sup>); doxorubicin, 298 mg/m<sup>2</sup> (target, 300 mg/m<sup>2</sup>); and cisplatin, 239 mg/m<sup>2</sup> (target, 240 mg/<sup>2</sup>; Data Supplement).</p></sec></sec><sec><title>IFN-&#x003b1;-2b</title><p>Of 357 patients randomly assigned to MAP plus IFN-&#x003b1;-2b, 82 (23%) reported not starting; information was missing for four (1%). The most common reason for not starting was treatment refusal (78%; <xref ref-type="fig" rid="F2">Fig 2</xref>). Of the 357 patients, 271 (76%) started IFN-&#x003b1;-2b at median 23 weeks after random assignment. At data freeze, 128 (47%) of these 271 patients reported completing protocol treatment, 105 (39%) of 271 reported stopping early, and 38 (14%) of 271 reported still receiving treatment. Reported reasons for early termination were: toxicity (n = 47; 45%), osteosarcoma progression (n = 25; 24%), refusal or patient choice (n = 18; 17%), clinician decision (n = 7; 7%), problems with wound healing or periprosthetic infections (n = 6; 6%), and other reasons (pregnancy, n = 1; lost, n = 1; <xref ref-type="fig" rid="F2">Fig 2</xref>). Of the 271 patients, 132 (49%) required IFN-&#x003b1;-2b dose reductions or delays. The target cumulative IFN-&#x003b1;-2b dose was 72 &#x003bc;g/kg. In 319 patients who could have completed IFN-&#x003b1;-2b by the data freeze, the observed median dose was 25.8 &#x003bc;g/kg (IQR, 0.5 to 60.0). Of these 319 patients, 240 reported starting IFN-&#x003b1;-2b; among these 240, median dose was 40.0 &#x003bc;g/kg (IQR, 14.5 to 65.0; Data Supplement). Median duration of therapy was 67 weeks (IQR, 25 to 75).</p></sec><sec><title>Efficacy</title><p>EFS at 3 years for all 716 randomly assigned patients was 76% (95% CI, 72% to 79%). A total of 174 events were reported (MAP, n = 93; MAP plus IFN-&#x003b1;-2b, n = 81; <xref ref-type="fig" rid="F2">Fig 2</xref>). In both arms, patients' first events mostly included metastases (MAP, n = 79; MAP plus IFN-&#x003b1;-2b, n = 70). Local recurrence was involved in 22 of the 174 first events (MAP, n = 11; MAP plus IFN-&#x003b1;-2b, n = 11). Of these, 17 were isolated local recurrences, and five were combined with distant metastases. One secondary malignancy (acute myeloid leukemia) was reported as a first event (MAP-alone arm). Type of first event was not reported for three patients (MAP, n = 1; MAP plus IFN-&#x003b1;-2b, n = 2).</p><p>Treatment effect for IFN-&#x003b1;-2b was estimated as HR of 0.83 (95% CI, 0.61 to 1.12; <italic>P</italic> = .214). Rates of 3-year EFS for MAP and MAP plus IFN-&#x003b1;-2b were 74% (95% CI, 69% to 79%) and 77% (95% CI, 72% to 81%), respectively (<xref ref-type="fig" rid="F3">Fig 3</xref>A).</p><fig id="F3" position="float"><label>Fig 3.</label><caption><p>(A) Event-free survival; (B) overall survival; (C) exploratory subgroup analysis; (D) exploratory comparison. Nos. in parentheses in risk tables of parts A, B, and D indicate No. of patients who had an event during the specified time period. HR, hazard ratio. IFN-&#x003b1;-2b, interferon alfa-2b; MAP, methotrexate, doxorubicin, and cisplatin.</p></caption><graphic xlink:href="zlj9991052830003"/></fig><p>In 630 patients with localized disease, 135 EFS events were reported (MAP, n = 72; MAP plus IFN-&#x003b1;-2b, n = 63). The estimated treatment effect was consistent with the whole trial population (HR, 0.83; 95% CI, 0.59 to 1.17; <italic>P</italic> = .284); 3-year EFS estimates were 77% (95% CI, 71% to 82%) and 80% (95% CI, 75% to 84%) for MAP and MAP plus IFN-&#x003b1;-2b, respectively.</p><p>A total of 84 deaths were reported (MAP, n = 46; MAP plus IFN-&#x003b1;-2b, n = 38; <xref ref-type="fig" rid="F3">Fig 3</xref>B). This early estimate of survival had an HR of 0.77 (95% CI, 0.50 to 1.19); 5-year OS was 81% (95% CI, 74% to 86%) for MAP and 84% (95% CI, 78% to 88%) for MAP plus IFN-&#x003b1;-2b. Follow-up continues for survival.</p></sec><sec><title>Toxicity</title><p>The toxicity of preoperative chemotherapy has previously been reported.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> During postoperative MAP, toxicity was mostly hematologic and did not differ by arm (Data Supplement). One patient died as a result of toxicity (cardiomyopathy); worst toxicity was grade 4 for 628 (88%) and grade 3 for 59 (8%) of 716 patients.</p><p>With regard to IFN-&#x003b1;-2b, toxicity data were reported for 268 of 271 patients who started IFN-&#x003b1;-2b. No fatal toxicities were reported (<xref ref-type="table" rid="T2">Table 2</xref>). The worst toxicity during IFN-&#x003b1;-2b was grade 4 for 32 (12%) of 268 patients (primarily hematologic [n = 26] or left ventricular systolic dysfunction [LVSD; n = 4]); grade 3 was worst toxicity for 101 (38%) and grade 1 to 2 for 105 (39%) of 268 patients. Three suspected unexpected serious adverse reactions related to IFN-&#x003b1;-2b were reported: two new cases of LVSD and one knee joint effusion.</p><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>Worst-Grade Toxicities Reported During IFN-&#x003b1;2b Treatment</p></caption><alternatives><graphic xlink:href="zlj02015-5283-t02"/><table frame="box" rules="groups"><thead valign="bottom"><tr><th align="center" rowspan="3" colspan="1">Toxicity</th><th align="center" colspan="8" rowspan="1">Worst Grade<hr/></th></tr><tr><th align="center" colspan="2" rowspan="1">0<hr/></th><th align="center" colspan="2" rowspan="1">1-2<hr/></th><th align="center" colspan="2" rowspan="1">3<hr/></th><th align="center" colspan="2" rowspan="1">4<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%<xref ref-type="table-fn" rid="TF2-1">*</xref></th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%<xref ref-type="table-fn" rid="TF2-1">*</xref></th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%<xref ref-type="table-fn" rid="TF2-1">*</xref></th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%<xref ref-type="table-fn" rid="TF2-1">*</xref></th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Any</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">105</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">101</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">Routinely collected toxicities<xref ref-type="table-fn" rid="TF2-2">&#x02020;</xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Neutrophils</td><td align="char" char="." rowspan="1" colspan="1">72</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">39</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">65</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Leucocytes</td><td align="char" char="." rowspan="1" colspan="1">76</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">158</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Platelets</td><td align="char" char="." rowspan="1" colspan="1">142</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">112</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Mood alteration (depression)</td><td align="char" char="." rowspan="1" colspan="1">193</td><td align="char" char="." rowspan="1" colspan="1">75</td><td align="char" char="." rowspan="1" colspan="1">55</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Fever</td><td align="char" char="." rowspan="1" colspan="1">156</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">107</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Hemoglobin</td><td align="char" char="." rowspan="1" colspan="1">131</td><td align="char" char="." rowspan="1" colspan="1">49</td><td align="char" char="." rowspan="1" colspan="1">127</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Fatigue</td><td align="char" char="." rowspan="1" colspan="1">134</td><td align="char" char="." rowspan="1" colspan="1">50</td><td align="char" char="." rowspan="1" colspan="1">129</td><td align="char" char="." rowspan="1" colspan="1">49</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Cardiac arrhythmia</td><td align="char" char="." rowspan="1" colspan="1">243</td><td align="char" char="." rowspan="1" colspan="1">96</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Rigor/chills</td><td align="char" char="." rowspan="1" colspan="1">202</td><td align="char" char="." rowspan="1" colspan="1">75</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Vomiting</td><td align="char" char="." rowspan="1" colspan="1">236</td><td align="char" char="." rowspan="1" colspan="1">89</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Diarrhea</td><td align="char" char="." rowspan="1" colspan="1">239</td><td align="char" char="." rowspan="1" colspan="1">90</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Bilirubin</td><td align="char" char="." rowspan="1" colspan="1">245</td><td align="char" char="." rowspan="1" colspan="1">92</td><td align="char" char="." rowspan="1" colspan="1">18</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Weight loss</td><td align="char" char="." rowspan="1" colspan="1">231</td><td align="char" char="." rowspan="1" colspan="1">87</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Thyroid dysfunction</td><td align="char" char="." rowspan="1" colspan="1">242</td><td align="char" char="." rowspan="1" colspan="1">92</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Creatinine</td><td align="char" char="." rowspan="1" colspan="1">250</td><td align="char" char="." rowspan="1" colspan="1">94</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Mucositis</td><td align="char" char="." rowspan="1" colspan="1">174</td><td align="char" char="." rowspan="1" colspan="1">94</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Other notable serious AEs and toxicities<xref ref-type="table-fn" rid="TF2-3">&#x02021;</xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;LVSD</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Amylase</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Mood alteration (agitation)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Infection (normal neutrophils)<xref ref-type="table-fn" rid="TF2-4">&#x000a7;</xref></td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Flu-like syndrome</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pain (muscle)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pain (head/headache)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Pain (extremity/limb)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives><table-wrap-foot><fn fn-type="other"><p>NOTE. Includes all routinely collected toxicities and any other toxicities with reported incidence in &#x02265; five patients of any grade or of grade &#x02265; 4 in one patient.</p></fn><fn fn-type="abbr"><p>Abbreviations: AE, adverse event; CRF, case report form; IFN-&#x003b1;2b, interferon alfa-2b; LVSD, left ventricular systolic dysfunction; NA, not applicable.</p></fn><fn fn-type="other" id="TF2-1"><label>*</label><p>Based on No. of patients reporting each type of toxicity.</p></fn><fn fn-type="other" id="TF2-2"><label>&#x02020;</label><p>Routinely collected on CRF.</p></fn><fn fn-type="other" id="TF2-3"><label>&#x02021;</label><p>Spontaneously reported on CRF or as serious AE.</p></fn><fn fn-type="other" id="TF2-4"><label>&#x000a7;</label><p>Or grade 1 to 2 neutrophils.</p></fn></table-wrap-foot></table-wrap><p>From routinely collected long-term toxicity data, seven (4%) of 193 patients receiving MAP and eight (4%) of 199 patients receiving MAP plus IFN-&#x003b1;-2b reported grade 3 to 4 LVSD (Data Supplement). One additional grade 4 LVSD was reported as a serious adverse event during follow-up.</p></sec><sec><title>Exploratory Analyses</title><p>Exploratory subgroup analyses found no evidence of heterogeneity in treatment effect (<xref ref-type="fig" rid="F3">Fig 3</xref>C; Data Supplement). An exploratory EFS analysis (<xref ref-type="fig" rid="F3">Fig 3</xref>D) separated patients allocated to MAP plus IFN-&#x003b1;-2b who started IFN-&#x003b1;-2b from those who did not start and compared them with patients allocated to MAP. Patients who did not start their allocated IFN-&#x003b1;-2b seemed to do worse than patients not allocated to IFN-&#x003b1;-2b. The exploratory analysis of EFS computed from 23 weeks after start of postoperative chemotherapy included 702 patients who had not previously experienced progression. HR was 0.83 (95% CI, 0.61 to 1.12), similar to the overall EFS estimate.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We investigated maintenance pegylated IFN-&#x003b1;-2b for patients whose resectable osteosarcomas showed good histologic response to MAP induction chemotherapy. The point estimate of treatment effect showed improved EFS and OS. However, neither was statistically significant, and the CIs were consistent with no effect. No change in practice is indicated by these data.</p><p>We were able to ask this question, as well as a parallel question concerning chemotherapy intensification in patients whose osteosarcomas had poor histologic response, only because of the cooperative efforts of four multi-institutional groups.<sup><xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref></sup> This will provide a framework for future trials.</p><p>With an age range up to 40 years and inclusion of patients with resectable axial and/or primary metastatic disease, our study had broader eligibility than many others. However, all patients had their primary tumors resected, and all of these had shown a good response to chemotherapy. The observed 3-year EFS of 76% for the 716 randomly assigned patients meeting our eligibility criteria is in the range of those previously observed for good responders.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B28" ref-type="bibr">28</xref></sup> Approximately four fifths of first events were exclusively metastatic, and there was no suggestion of an altered distribution of type of event by treatment arm.</p><p>Toxicity observed during preoperative MAP was as expected<sup><xref rid="B7" ref-type="bibr">7</xref></sup> and did not differ by allocation. Death related to toxicity during postoperative MAP was limited to one case of cardiomyopathy. Nevertheless, most patients reported grade 4 toxicities, mostly hematologic, attesting to the treatment burden of osteosarcoma chemotherapy. As expected,<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B29" ref-type="bibr">29</xref></sup> toxicities observed during IFN-&#x003b1;-2b were mainly grade 1 to 2. However, grade 3 and 4 toxicities were reported for one half of patients who started IFN-&#x003b1;-2b, mostly hematologic. Several patients developed signs of cardiac failure during IFN-&#x003b1;-2b. Although we cannot exclude a contribution from IFN-&#x003b1;-2b to this complication, we note these patients had previously received doxorubicin 450 mg/m<sup>2</sup> and that a similar number of control-arm patients also developed LVSD. Given the high cumulative anthracycline dose, the overall incidence of severe clinical cardiac toxicity in this mainly adolescent population receiving a high cumulative anthracycline dose by continuous infusion, rather than as a bolus, does not seem excessive.<sup><xref rid="B30" ref-type="bibr">30</xref></sup></p><p>The point estimates of the HR favored IFN-&#x003b1;-2b maintenance for both EFS and OS, but the CIs were consistent with no effect. The observed effect size for EFS (HR, 0.83; 95% CI, 0.61 to 1.12) was similar to that reported for another biologic agent, liposomal muramyl tripeptide phosphatidylethanolamine (HR, 0.80; 95% CI, 0.62 to 1.0),<sup><xref rid="B8" ref-type="bibr">8</xref></sup> but smaller than our 0.63 target.</p><p>The interpretation of our findings is limited, because approximately one quarter of patients allocated to IFN-&#x003b1;-2b never started it. Furthermore, not all patients continued IFN-&#x003b1;-2b after having started; only 128 of 357 patients reported completing the planned protocol treatment. These issues of initiation and adherence arose even though neither the dose nor schedule of IFN-&#x003b1;-2b nor the duration of treatment was unusual,<sup><xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B31" ref-type="bibr">31</xref></sup> and a pegylated preparation was expected to result in fewer adverse effects.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B16" ref-type="bibr">16</xref></sup></p><p>One may speculate why the attrition rate for IFN-&#x003b1;-2b was high. Patient choice was the most common reason for non&#x02013;random assignment and for never starting IFN-&#x003b1;-2b among allocated patients and a common reason for its premature termination. We assume that both previous exposure to 29 protocol weeks of chemotherapy and awareness of a favorable prognosis for good responders affected compliance. A recent RCT of IFN-&#x003b1; maintenance for relapsed lymphoma faced similar abandonment problems. Those researchers concluded that it was not clear whether the absence of a demonstrable advantage reflected a lack of intrinsic activity or indicated the inability to administer an adequate dose of IFN to patients for sustained periods.<sup><xref rid="B32" ref-type="bibr">32</xref></sup></p><p>At first glance, our observations might call for an as-treated analysis comparing those who initiated IFN-&#x003b1;-2b against the control arm. However, patients allocated to IFN-&#x003b1;-2b who never started the drug fared worse than patients never allocated to receive IFN-&#x003b1;-2b in the first place, for reasons that are currently obscure.</p><p>Would a treatment effect have become more obvious if the chosen IFN-&#x003b1;-2b dose had been higher or the treatment period longer? Even in melanoma, where many RCTs of IFN have been performed, evidence supporting a specific IFN dose, duration, or formulation and identification of subsets of patients beyond those with detectable residual disease most likely to benefit remain debatable issues, with no RCT showing additional benefit for treatment extending beyond 12 to 18 months.<sup><xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B33" ref-type="bibr">33</xref></sup> For osteosarcoma, such evidence is completely absent. The timing of IFN-&#x003b1;-2b therapy is similarly uncertain. Although IFN-&#x003b1; may enhance the sensitivity of osteosarcomas to selected chemotherapeutic agents,<sup><xref rid="B34" ref-type="bibr">34</xref></sup> there are no data demonstrating that IFN-&#x003b1;-2b can be safely administered concurrently with MAP and no data indicating that it would be more efficacious.</p><p>Was the good responder cohort, with its relatively low recurrence risk, ideal to observe effects of IFN-&#x003b1;-2b? Good responders generally have a lower burden of micrometastatic residual disease (because of chemosensitivity of their osteosarcomas) than poor responders, and IFN may work best in such a context of minimal residual disease. This is exemplified by adjuvant data from melanoma, where IFN activity was confined to a subpopulation with microscopic nodal disease.<sup><xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B35" ref-type="bibr">35</xref></sup></p><p>In conclusion, our collaborative group completed a large prospective RCT in a rare condition within a reasonable timespan. Although the point estimates for EFS and OS favored the intervention&#x02014;maintenance with pegylated IFN-&#x003b1;-2b&#x02014;the CIs of the HRs included 1, and we conclude no difference; the observed effect size for EFS was smaller than targeted. A considerable proportion of patients allocated to IFN-&#x003b1;-2b never started or did not complete treatment with the drug, which complicates interpretation of the efficacy data. Reported toxicity in patients who started IFN-&#x003b1;-2b did not seem excessive.</p><p>Although we have reached the target number of EFS events, ongoing follow-up of patients is crucial and will permit the planned analysis of OS. The current EFS results, reported at the protocol-defined analytic end point, do not support the routine use of IFN-&#x003b1;-2b maintenance after standard chemotherapy for osteosarcoma.</p></sec></body><back><fn-group><fn fn-type="other"><p>Listen to the podcast by Dr Arndt at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org/podcasts">www.jco.org/podcasts</ext-link></p></fn><fn fn-type="supported-by"><p>Support information appears at the end of this article.</p></fn><fn fn-type="other"><p>Terms in blue are defined in the glossary, found at the end of this article and online at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>.</p></fn><fn fn-type="other"><p>Trial unit staff at the Medical Research Council Clinical Trials Unit of University College London, Children's Oncology Group, Cooperative Osteosarcoma Study Group, Scandinavian Sarcoma Group, EURAMOS Intergroup Safety Desk, and Quality of Life Coordinating Centre were central to the trial design, trial conduct, data analysis, data interpretation, and development of this report. S.S.B., G.J., J.M.H., T.B.-B., and M.R.S. accessed raw data. The corresponding author had full access to the data and had final responsibility for the decision to submit for publication.</p></fn><fn fn-type="conflict"><p>Authors' disclosures of potential conflicts of interest are found in the article online at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>. Author contributions are found at the end of this article.</p></fn><fn fn-type="other"><p>Clinical trial information: NCT00134030; ISRCTN67613327.</p></fn></fn-group><fn-group><title>Support</title><fn fn-type="supported-by"><p>Supported by governmental, nongovernmental, scientific, and charitable body funders in each participating country, with additional funding for pan-European trial coordination. Pegylated interferon-alfa-2b was provided by Merck, which reviewed this report. EURAMOS-1 was supported by multiple national and international governmental agencies and cancer charities, including the National Cancer Institute, which provided funding to the Children's Oncology Group (North America, Australasia, and Switzerland); the European Science Foundation under the EUROCORES Program European Clinical Trials through Contract No. ERASCT-2003-980409 from the European Commission, DG Research, FP6 (Reference No. MM/NG/EMRC/0202); St Anna Kinderkrebsforschung (Austria); Fonds National de la Recherche Scientifique and Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (Belgium); Parents Organisation (Czech Republic); Danish Medical Research Council (Denmark); Academy of Finland (Finland); Deutsche Forschungsgemeinschaft Ref No. BI 1045/1-1 &#x00026; 1-2), Deutsche Krebshilfe (Reference No. 50-2723-Bi2), and Federal Ministry of Education and Research (Reference No. BMBF 01KN1105; Germany); Semmelweis Foundation (Hungary); Council for Medical Research (the Netherlands); Research Council of Norway (Norway); Scandinavian Sarcoma Group (Sweden); Swiss Paediatric Oncology Group (Switzerland); Cancer Research UK (Reference No. CRUK/05/013), Medical Research Council, National Institute for Health Research at University College London Hospitals, and Biomedical Research Centre (United Kingdom).</p></fn></fn-group><ack><title>Acknowledgment</title><p>We acknowledge the input of Mahesh K.B. Parmar, James Pickering, Nicola Joffe, Anne Holliday, Karen Sanders, Monique Tomiczek, Beth May, Matthias Kevric, Benjamin Sorg, Doojduen Villaluna, Caroline Wang, Martha Perisoglou, Leonardo Trani, Jenny Potratz, Dorothe Carrle, Miriam Wilhelm, Katja Zils, and Carmen Teske.</p><p>Presented in part at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013.</p></ack><sec><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><p>Disclosures provided by the authors are available with this article at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>.</p></sec><sec><title>AUTHOR CONTRIBUTIONS</title><p><bold>Conception and design:</bold> Stefan S. Bielack, Sigbj&#x000f8;rn Smeland, Jeremy S. Whelan, Neyssa Marina, Paul Meyers, Gabriele Calaminus, Matthew R. Sydes, Mark Bernstein</p><p><bold>Provision of study materials or patients:</bold> Stefan S. Bielack, Sigbj&#x000f8;rn Smeland, Jeremy S. Whelan, Neyssa Marina, Gordana Jovic, Jane M. Hook, Mark D. Krailo, Mark Gebhardt, Zsuzsanna P&#x000e1;pai, James Meyer, Helen Nadel, R. Lor Randall, Claudia Deffenbaugh, Rajaram Nagarajan, Bernadette Brennan, G. Douglas Letson, Lisa A. Teot, Allen Goorin, Daniel Baumhoer, Leo Kager, Mathias Werner, Ching C. Lau, Kirsten Sundby Hall, Hans Gelderblom, Richard Gorlick, Reinhard Windhager, Knut Helmke, Mikael Eriksson, Peter M. Hoogerbrugge, Paula Schomberg, Per-Ulf Tunn, Thomas K&#x000fc;hne, Heribert J&#x000fc;rgens, Henk van den Berg, Tom B&#x000f6;hling, Susan Picton, Marleen Renard, Peter Reichardt, Joachim Gerss, Trude Butterfass-Bahloul, Carol Morris, Pancras C.W. Hogendoorn, Beatrice Seddon, Gabriele Calaminus, Maria Michelagnoli, Catharina Dhooge, Matthew R. Sydes, Mark Bernstein</p><p><bold>Collection and assembly of data:</bold> Stefan S. Bielack, Sigbj&#x000f8;rn Smeland, Jeremy S. Whelan, Neyssa Marina, Gordana Jovic, Jane M. Hook, Mark D. Krailo, Mark Gebhardt, Zsuzsanna P&#x000e1;pai, James Meyer, Helen Nadel, R. Lor Randall, Claudia Deffenbaugh, Rajaram Nagarajan, Bernadette Brennan, G. Douglas Letson, Lisa A. Teot, Allen Goorin, Daniel Baumhoer, Leo Kager, Mathias Werner, Ching C. Lau, Kirsten Sundby Hall, Hans Gelderblom, Richard Gorlick, Reinhard Windhager, Knut Helmke, Mikael Eriksson, Peter M. Hoogerbrugge, Paula Schomberg, Per-Ulf Tunn, Thomas K&#x000fc;hne, Heribert J&#x000fc;rgens, Henk van den Berg, Tom B&#x000f6;hling, Susan Picton, Marleen Renard, Peter Reichardt, Joachim Gerss, Trude Butterfass-Bahloul, Carol Morris, Pancras C.W. Hogendoorn, Beatrice Seddon, Gabriele Calaminus, Maria Michelagnoli, Catharina Dhooge, Matthew R. Sydes, Mark Bernstein</p><p><bold>Data analysis and interpretation:</bold> Stefan S. Bielack, Sigbj&#x000f8;rn Smeland, Jeremy S. Whelan, Neyssa Marina, Gordana Jovic, Jane M. Hook, Paul Meyers, Trude Butterfass-Bahloul, Matthew R. Sydes, Mark Bernstein</p><p><bold>Manuscript writing:</bold> All authors</p><p><bold>Final approval of manuscript:</bold> All authors</p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gorlick</surname><given-names>R</given-names></name><name><surname>Bielack</surname><given-names>S</given-names></name><name><surname>Teot</surname><given-names>L</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Pizzo</surname><given-names>P</given-names></name><name><surname>Poplack</surname><given-names>D</given-names></name></person-group><article-title>Osteosarcoma: Biology, diagnosis, treatment, and remaining challenges</article-title><source>Principles and Practice of Pediatric Oncology (ed 6)</source><year>2011</year><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Lippincott Williams and Wilkins</publisher-name><fpage>1015</fpage><lpage>1044</lpage></element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirabello</surname><given-names>L</given-names></name><name><surname>Troisi</surname><given-names>RJ</given-names></name><name><surname>Savage</surname><given-names>SA</given-names></name></person-group><article-title>Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>1531</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">19197972</pub-id></element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>CA</given-names></name><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Jundt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Bone tumours in European children and adolescents, 1978-1997: Report from the Automated Childhood Cancer Information System project</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><fpage>2124</fpage><lpage>2135</lpage><pub-id pub-id-type="pmid">16919776</pub-id></element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Kempf-Bielack</surname><given-names>B</given-names></name><name><surname>Delling</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>776</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">11821461</pub-id></element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielack</surname><given-names>S</given-names></name><name><surname>J&#x000fc;rgens</surname><given-names>H</given-names></name><name><surname>Jundt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Osteosarcoma: The COSS experience</article-title><source>Cancer Treat Res</source><year>2009</year><volume>152</volume><fpage>289</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">20213397</pub-id></element-citation></ref><ref id="B6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bruland</surname><given-names>&#x000d8;S</given-names></name><name><surname>Bauer</surname><given-names>H</given-names></name><name><surname>Alvegaard</surname><given-names>T</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Jaffe</surname><given-names>N</given-names></name><name><surname>Bruland</surname><given-names>OS</given-names></name><name><surname>Stefan</surname><given-names>B</given-names></name></person-group><article-title>Treatment of osteosarcoma: The Scandinavian Sarcoma Group experience</article-title><source>Pediatric and Adolescent Osteosarcoma: Series&#x02014;Cancer Treatment and Research</source><year>2009</year><publisher-loc>New York, NY</publisher-loc><publisher-name>Springer</publisher-name><fpage>309</fpage><lpage>318</lpage></element-citation></ref><ref id="B7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Schwartz</surname><given-names>CL</given-names></name><name><surname>Krailo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2004</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">15774791</pub-id></element-citation></ref><ref id="B8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Schwartz</surname><given-names>CL</given-names></name><name><surname>Krailo</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival&#x02014;A report from the Children's Oncology Group</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">18235123</pub-id></element-citation></ref><ref id="B9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>JS</given-names></name><name><surname>Jinks</surname><given-names>RC</given-names></name><name><surname>McTiernan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Survival from high-grade localised extremity osteosarcoma: Combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><fpage>1607</fpage><lpage>1616</lpage><pub-id pub-id-type="pmid">22015453</pub-id></element-citation></ref><ref id="B10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marina</surname><given-names>N</given-names></name><name><surname>Bielack</surname><given-names>S</given-names></name><name><surname>Whelan</surname><given-names>J</given-names></name><etal/></person-group><article-title>International collaboration is feasible in trials for rare conditions: The EURAMOS experience</article-title><source>Cancer Treat Res</source><year>2009</year><volume>152</volume><fpage>339</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">20213400</pub-id></element-citation></ref><ref id="B11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>JS</given-names></name><name><surname>Bielack</surname><given-names>SS</given-names></name><name><surname>Marina</surname><given-names>N</given-names></name><etal/></person-group><article-title>EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">25421877</pub-id></element-citation></ref><ref id="B12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smeland</surname><given-names>S</given-names></name><name><surname>Bruland</surname><given-names>OS</given-names></name><name><surname>Hjorth</surname><given-names>L</given-names></name><etal/></person-group><article-title>Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years</article-title><source>Acta Orthop</source><year>2011</year><volume>82</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">21434784</pub-id></element-citation></ref><ref id="B13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>J</given-names></name><name><surname>Patterson</surname><given-names>D</given-names></name><name><surname>Perisoglou</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of interferons in the treatment of osteosarcoma</article-title><source>Pediatr Blood Cancer</source><year>2010</year><volume>54</volume><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">19902521</pub-id></element-citation></ref><ref id="B14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there?</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>1165</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">22730540</pub-id></element-citation></ref><ref id="B15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Le Cesne</surname><given-names>A</given-names></name></person-group><article-title>A role for maintenance therapy in managing sarcoma</article-title><source>Cancer Treat Rev</source><year>2012</year><volume>38</volume><fpage>368</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">21843915</pub-id></element-citation></ref><ref id="B16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Tendler</surname><given-names>C</given-names></name><name><surname>Cutler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Treating cancer with PEG intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation</article-title><source>Cancer</source><year>2002</year><volume>95</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">12124839</pub-id></element-citation></ref><ref id="B17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritz</surname><given-names>E</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name></person-group><article-title>Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients</article-title><source>Ann Oncol</source><year>2000</year><volume>11</volume><fpage>1427</fpage><lpage>1436</lpage><pub-id pub-id-type="pmid">11142483</pub-id></element-citation></ref><ref id="B18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Butterfield</surname><given-names>LH</given-names></name><name><surname>Tarhini</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Immunotherapy of cancer in 2012</article-title><source>CA Cancer J Clin</source><year>2012</year><volume>62</volume><fpage>309</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">22576456</pub-id></element-citation></ref><ref id="B19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarhini</surname><given-names>AA</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name></person-group><article-title>How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>3773</fpage><lpage>3776</lpage><pub-id pub-id-type="pmid">23008298</pub-id></element-citation></ref><ref id="B20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Shimose</surname><given-names>S</given-names></name><name><surname>Matsuo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Interferon-alpha/beta receptor as a prognostic marker in osteosarcoma</article-title><source>J Bone Joint Surg Am</source><year>2011</year><volume>93</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">21411701</pub-id></element-citation></ref><ref id="B21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>CR</given-names></name><name><surname>Smeland</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series</article-title><source>Acta Oncol</source><year>2005</year><volume>44</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">16118081</pub-id></element-citation></ref><ref id="B22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaud</surname><given-names>AP</given-names></name><name><surname>Bauman</surname><given-names>NM</given-names></name><name><surname>Burke</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Spastic diplegia and other motor disturbances in infants receiving interferon-alpha</article-title><source>Laryngoscope</source><year>2004</year><volume>114</volume><fpage>1231</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">15235352</pub-id></element-citation></ref><ref id="B23"><label>23.</label><element-citation publication-type="webpage"><collab>National Cancer Institute</collab><article-title>Common Terminology Criteria for Adverse Events (version 3.0)</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf</ext-link></comment></element-citation></ref><ref id="B24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>SL</given-names></name><name><surname>Desu</surname><given-names>MM</given-names></name></person-group><article-title>Planning the size and duration of a clinical trial studying the time to some critical event</article-title><source>J Chron Dis</source><year>1974</year><volume>27</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">4592596</pub-id></element-citation></ref><ref id="B25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haybittle</surname><given-names>JL</given-names></name></person-group><article-title>Repeated assessment of results in clinical trials of cancer treatment</article-title><source>Br J Radiol</source><year>1971</year><volume>44</volume><fpage>793</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">4940475</pub-id></element-citation></ref><ref id="B26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Armitage</surname><given-names>P</given-names></name><etal/></person-group><article-title>Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design</article-title><source>Br J Cancer</source><year>1976</year><volume>34</volume><fpage>585</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">795448</pub-id></element-citation></ref><ref id="B27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Deley</surname><given-names>MC</given-names></name><name><surname>Guinebreti&#x000e8;re</surname><given-names>JM</given-names></name><name><surname>Gentet</surname><given-names>JC</given-names></name><etal/></person-group><article-title>SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><fpage>752</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">17267204</pub-id></element-citation></ref><ref id="B28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Soon</surname><given-names>C</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma</article-title><source>Expert Opin Biol Ther</source><year>2012</year><volume>12</volume><fpage>1087</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">22694288</pub-id></element-citation></ref><ref id="B29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dalen</surname><given-names>EC</given-names></name><name><surname>van der Pal</surname><given-names>HJ</given-names></name><name><surname>Caron</surname><given-names>HN</given-names></name><etal/></person-group><article-title>Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>4</volume><fpage>CD005008</fpage><pub-id pub-id-type="pmid">19821337</pub-id></element-citation></ref><ref id="B30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakacki</surname><given-names>RI</given-names></name><name><surname>Dombi</surname><given-names>E</given-names></name><name><surname>Potter</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas</article-title><source>Neurology</source><year>2011</year><volume>76</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">21242495</pub-id></element-citation></ref><ref id="B31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosly</surname><given-names>A</given-names></name><name><surname>Grigg</surname><given-names>A</given-names></name><name><surname>Holte</surname><given-names>H</given-names></name><etal/></person-group><article-title>A randomized study of interferon alpha-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma</article-title><source>Oncologist</source><year>2013</year><volume>18</volume><fpage>1189</fpage><pub-id pub-id-type="pmid">24105750</pub-id></element-citation></ref><ref id="B32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Kudchadkar</surname><given-names>R</given-names></name></person-group><article-title>Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><fpage>1223</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">23002125</pub-id></element-citation></ref><ref id="B33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>SF</given-names></name><name><surname>An</surname><given-names>T</given-names></name><name><surname>Worth</surname><given-names>L</given-names></name><etal/></person-group><article-title>Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide</article-title><source>J Interferon Cytokine Res</source><year>1999</year><volume>19</volume><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">10433362</pub-id></element-citation></ref><ref id="B34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Suciu</surname><given-names>S</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>3810</fpage><lpage>3818</lpage><pub-id pub-id-type="pmid">23008300</pub-id></element-citation></ref><ref id="B35"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Unni</surname><given-names>KK</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><source>World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone</source><year>2002</year><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Press</publisher-name></element-citation></ref></ref-list><glossary><title>Glossary Terms</title><def-list><def-item><term id="G1">cisplatin:</term><def><p>an inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes, which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Carboplatin and oxaliplatin are other members of this class.</p></def></def-item><def-item><term id="G2">Cox proportional hazards regression model:</term><def><p>a statistical model for regression analysis of censored survival data, examining the relationship of censored survival distribution to one or more covariates. This model produces a baseline survival curve, covariate coefficient estimates with their standard errors, risk ratios, 95% CIs, and significance levels.</p></def></def-item><def-item><term id="G3">IFN-&#x003b1;-2b (interferon-alfa-2b):</term><def><p>recombinant interferon alfa that is commercially prepared from a bacterial fermentation of <italic>E. coli</italic> bearing an expression vector containing the interferon alfa-2b (<italic>IFN</italic>-&#x003b1;-<italic>2b</italic>) gene from human leukocytes.</p></def></def-item></def-list></glossary><sec><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><sec><title>Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial</title><p><italic>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://jco.ascopubs.org/site/ifc">jco.ascopubs.org/site/ifc</ext-link></italic>.</p></sec><sec><title>Stefan S. Bielack</title><p><bold>Consulting or Advisory Role:</bold> Celgene, Bayer, Chugai Pharma, Clinigen</p><p><bold>Research Funding:</bold> Novartis (Inst), Janssen-Cilag (Inst)</p></sec><sec><title>Sigbj&#x000f8;rn Smeland</title><p>No relationship to disclose</p></sec><sec><title>Jeremy S. Whelan</title><p>No relationship to disclose</p></sec><sec><title>Neyssa Marina</title><p><bold>Honoraria:</bold> Jazz Pharmaceuticals</p><p><bold>Consulting or Advisory Role:</bold> Jazz Pharmaceuticals</p></sec><sec><title>Gordana Jovic</title><p>No relationship to disclose</p></sec><sec><title>Jane M. Hook</title><p><bold>Travel, Accommodations, Expenses:</bold> Clovis Oncology</p></sec><sec><title>Mark D. Krailo</title><p>No relationship to disclose</p></sec><sec><title>Mark Gebhardt</title><p><bold>Patents, Royalties, Other Intellectual Property:</bold> Royalties for authoring/editing on medical topics for UpToDate</p><p><bold>Other Relationship:</bold> Clinical Orthopaedic and Related Research</p></sec><sec><title>Zsuzsanna P&#x000e1;pai</title><p>No relationship to disclose</p></sec><sec><title>James Meyer</title><p>No relationship to disclose</p></sec><sec><title>Helen Nadel</title><p>No relationship to disclose</p></sec><sec><title>R. Lor Randall</title><p><bold>Honoraria:</bold> Biomet</p><p><bold>Research Funding:</bold> Musculoskeletal Transplant Foundation</p><p><bold>Travel, Accommodations, Expenses:</bold> Biomet</p></sec><sec><title>Claudia Deffenbaugh</title><p>No relationship to disclose</p></sec><sec><title>Rajaram Nagarajan</title><p>No relationship to disclose</p></sec><sec><title>Bernadette Brennan</title><p>No relationship to disclose</p></sec><sec><title>G. Douglas Letson</title><p><bold>Consulting or Advisory Role:</bold> Stryker</p><p><bold>Travel, Accommodations, Expenses:</bold> Stryker</p></sec><sec><title>Lisa A. Teot</title><p>No relationship to disclose</p></sec><sec><title>Allen Goorin</title><p>No relationship to disclose</p></sec><sec><title>Daniel Baumhoer</title><p>No relationship to disclose</p></sec><sec><title>Leo Kager</title><p><bold>Travel, Accommodations, Expenses:</bold> Novartis</p></sec><sec><title>Mathias Werner</title><p>No relationship to disclose</p></sec><sec><title>Ching C. Lau</title><p>No relationship to disclose</p></sec><sec><title>Kirsten Sundby Hall</title><p><bold>Patents, Royalties, Other Intellectual Property:</bold> Inven 2 (I)</p></sec><sec><title>Hans Gelderblom</title><p>No relationship to disclose</p></sec><sec><title>Paul Meyers</title><p><bold>Stock or Other Ownership:</bold> Amgen, Bayer, Dupont, Henry Schein, Jazz Pharmaceuticals, Mednax, Novartis, Procter and Gamble, Sigma-Aldrich</p><p><bold>Honoraria:</bold> France Foundation (I)</p><p><bold>Consulting or Advisory Role:</bold> Boehringer Ingelheim (I)</p><p><bold>Speakers' Bureau:</bold> France Foundation (I)</p><p><bold>Travel, Accommodations, Expenses:</bold> Takeda Pharmaceuticals, Medison, InterMune (I)</p></sec><sec><title>Richard Gorlick</title><p><bold>Stock or Other Ownership:</bold> Oncolytics Biotech</p><p><bold>Consulting or Advisory Role:</bold> Oncolytics Biotech</p></sec><sec><title>Reinhard Windhager</title><p><bold>Consulting or Advisory Role:</bold> Boehringer Ingelheim, Pfizer, Stryker, DePuy, Takeda Pharmaceuticals</p></sec><sec><title>Knut Helmke</title><p>No relationship to disclose</p></sec><sec><title>Mikael Eriksson</title><p><bold>Honoraria:</bold> Bayer</p><p><bold>Consulting or Advisory Role:</bold> Isofol</p><p><bold>Travel, Accommodations, Expenses:</bold> GlaxoSmithKline, Swedish Orphan Biovitrum</p></sec><sec><title>Peter M. Hoogerbrugge</title><p>No relationship to disclose</p></sec><sec><title>Paula Schomberg</title><p>No relationship to disclose</p></sec><sec><title>Per-Ulf Tunn</title><p>No relationship to disclose</p></sec><sec><title>Thomas K&#x000fc;hne</title><p><bold>Consulting or Advisory Role:</bold> UCB Celltech</p><p><bold>Research Funding:</bold> Amgen, GlaxoSmithKline</p></sec><sec><title>Heribert J&#x000fc;rgens</title><p><bold>Consulting or Advisory Role:</bold> Takeda Pharmaceuticals (Inst)</p><p><bold>Travel, Accommodations, Expenses:</bold> Takeda Pharmaceuticals</p></sec><sec><title>Henk van den Berg</title><p>No relationship to disclose</p></sec><sec><title>Tom B&#x000f6;hling</title><p>No relationship to disclose</p></sec><sec><title>Susan Picton</title><p><bold>Research Funding:</bold> Merck (Inst), Roche (Inst)</p></sec><sec><title>Marleen Renard</title><p>No relationship to disclose</p></sec><sec><title>Peter Reichardt</title><p><bold>Honoraria:</bold> Novartis, Pfizer, Bayer, PharmaMar, Amgen, GlaxoSmithKline</p><p><bold>Consulting or Advisory Role:</bold> Novartis, Pfizer, Bayer, ARIAD Pharmaceuticals, Amgen</p><p><bold>Research Funding:</bold> Novartis (Inst)</p></sec><sec><title>Joachim Gerss</title><p>No relationship to disclose</p></sec><sec><title>Trude Butterfass-Bahloul</title><p>No relationship to disclose</p></sec><sec><title>Carol Morris</title><p>No relationship to disclose</p></sec><sec><title>Pancras C.W. Hogendoorn</title><p>No relationship to disclose</p></sec><sec><title>Beatrice Seddon</title><p><bold>Honoraria:</bold> Pfizer</p><p><bold>Travel, Accommodations, Expenses:</bold> PharmaMar, GlaxoSmithKline</p></sec><sec><title>Gabriele Calaminus</title><p>No relationship to disclose</p></sec><sec><title>Maria Michelagnoli</title><p>No relationship to disclose</p></sec><sec><title>Catharina Dhooge</title><p><bold>Travel, Accommodations, Expenses:</bold> Merck Sharp &#x00026; Dohme</p></sec><sec><title>Matthew R. Sydes</title><p><bold>Honoraria:</bold> Eli Lilly</p><p><bold>Research Funding:</bold> Astellas, Janssen-Cilag, Pfizer, Novartis, sanofi-aventis</p><p><bold>Travel, Accommodations, Expenses:</bold> Eli Lilly</p></sec><sec><title>Mark Bernstein</title><p>No relationship to disclose</p></sec></sec><app-group><app id="app1"><title>Appendix</title><sec><title/><sec><title>EURAMOS-1 Investigators and Participants</title></sec><sec><title>A1. Children's Oncology Group (COG)</title><sec><title>United States.</title><p>Advocate Hope Children's Hospital, Oak Lawn, IL (Dr Ammar Hayani); Advocate Lutheran General Hospital, Park Ridge, IL (Dr Jong Kwon); Albany Medical Center, Albany, NY (Dr Vikramjit Kanwar); Alfred I duPont Hospital for Children, Wilmington, DE (Dr Christopher Frantz); All Children's Hospital, St. Petersburg, FL (Dr Gregory Hale); Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL (Dr David Walterhouse); Baptist Hospital of Miami, Miami, FL (Dr Doured Daghistani); Baylor College of Medicine, Houston, TX (Dr Lisa Bomgaars); BI-LO Charities Children's Cancer Center, Greenville, SC (Dr Nichole Bryant); Bronson Methodist Hospital, Kalamazoo, MI (Dr Jeffrey Lobel); Brooke Army Medical Center, Fort Sam Houston, TX (Dr Della Howell); Brooklyn Hospital Center, New York, NY (Dr Swayamprabha Sadanandan); Broward Health Medical Center, Fort Lauderdale, FL (Dr Hector Rodriguez-Cortes); C S Mott Children's Hospital, Ann Arbor, MI (Dr Rajen Mody); Cardinal Glennon Children's Medical Center, St Louis, MO (Dr William Ferguson); Cardon Children's Medical Center, Mesa, AZ (Dr Xiaxin Li); Carilion Clinic Children's Hospital, Roanoke, VA (Dr Mandy Atkinson); Carolinas Medical Center/Levine Cancer Institute, Charlotte, NC (Dr Joel Kaplan); Cedars-Sinai Medical Center, Los Angeles, CA (Dr Fataneh (Fae) Majlessipour); Children's Healthcare of Atlanta - Egleston, Atlanta, GA (Dr Howard Katzenstein); Children's Hospital and Medical Center of Omaha, Omaha, NE (Dr Minnie Abromowitch); Children's Hospital and Research Center at Oakland, Oakland, CA (Dr Carla Golden); Children's Hospital Central California, Madera, CA (Dr Vonda Crouse); Children's Hospital Colorado, Aurora, CO (Dr Kelly Maloney); Children's Hospital Medical Center of Akron, Akron, OH (Dr Steven Kuerbitz); Children's Hospital of Alabama, Birmingham, AL (Dr Alyssa Reddy); Children's Hospital of Los Angeles, Los Angeles, CA (Dr Leo Mascarenhas); Children's Hospital of Philadelphia, Philadelphia, PA (Dr Frank Balis); Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA (Dr Arthur Ritchey); Children's Hospital-Main Campus, New Orleans, LA (Dr Lolie Yu); Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, MN (Dr Bruce Bostrom); Children's Mercy Hospitals and Clinics, Kansas City, MO (Dr Maxine Hetherington); Children's National Medical Center, Washington, DC (Dr Jeffrey Dome); Childrens Hospital of Orange County, Orange, CA (Dr Violet Shen); Childrens Hospital-King's Daughters, Norfolk, VA (Dr Eric Lowe); Cincinnati Children's Hospital Medical Center, Cincinatti, OH (Dr John Perentesis); City of Hope, Duarte, CA (Dr Anna Pawlowska); Cleveland Clinic Foundation, Cleveland, OH (Dr Margaret Thompson); Columbia University Medical Center, New York, NY (Dr Alice Lee); Connecticut Children's Medical Center, Hartford, CT (Dr Michael Isakoff); Cook Children's Medical Center, Fort Worth, TX (Dr Mary Meaghan Granger); Midwest Children's Cancer Center, Milwaukee, WI (Dr Michael Kelly); Miller Children's Hospital, Long Beach, CA (Dr Amanda Termuhlen); Mission Hospitals Inc, Asheville, NC (Dr Orren Beaty); Montefiore Medical Center - Moses Campus, Bronx, NY (Dr Rosanna Ricafort); Morristown Medical Center, Morristown, NJ (Dr Steven Halpern); Mount Sinai Medical Center, New York, NY (Dr Birte Wistinghausen); Natalie W Bryant Cancer Center, Tulsa, OK (Dr Gregory Kirkpatrick); Nationwide Children's Hospital, Colombus, OH (Dr Mark Ranalli); Naval Medical Center - Portsmouth, Fort Sam Houston, TX (Dr Della Howell); Naval Medical Center -San Diego, Fort Sam Houston, TX (Dr Della Howell); Nemours Children's Clinic - Jacksonville, Jacksonville, FL (Dr Eric Sandler); Nemours Children's Clinic - Pensacola, Pensacola, FL (Dr Jeffrey Schwartz); Nemours Childrens Clinic - Orlando, Orlando, FL (Dr Ramamoorthy Nagasubramanian); Nevada Cancer Research Foundation CCOP, Las Vegas, NV (Dr Jonathan Bernstein); New York Medical College, Valhalla, NY (Dr Mehmet Ozkaynak); Newark Beth Israel Medical Center, Newark, NJ (Dr Peri Kamalakar); Ochsner Clinic Foundation, New Orleans, LA (Dr Rajasekharan (Raj) Warrier); Oregon Health and Science University, Portland, OR (Dr Linda Stork); Palmetto Health Richland, Columbia, SC (Dr Ronnie Neuberg); Penn State Hershey Children's Hospital, Hershey, PA (Dr Lisa McGregor); Phoenix Childrens Hospital, Phoenix, AZ (Dr Jessica Boklan); Novant Health Presbyterian Medical Center, Charlotte, NC (Dr Paulette Bryant); Primary Children's Medical Center, Salt Lake City, UT (Dr Phillip Barnette); Providence Sacred Heart Medical Center and Children's Hospital, Spokane, WA (Dr Judy Felgenhauer); Rady Children's Hospital - San Diego, San Diego, CA (Dr William Roberts); Rainbow Babies and Childrens Hospital, Cleveland, OH (Dr Yousif (Joe) Matloub); Randall Children's Hospital at Legacy Emanuel, Portland, OR (Dr Janice Olson); Raymond Blank Children's Hospital, Des Moines, IA (Dr Wendy Woods-Swafford); Rhode Island Hospital, Providence, RI (Dr Kevin Schwartz); Riley Hospital for Children, Indianapolis, IN (Dr Robert Fallon); Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical, Denver, CO (Dr Jennifer Clark); Roswell Park Cancer Institute, Buffalo, NY (Dr Martin Brecher); Saint Barnabas Medical Center (Newark Beth Israel Medical Center), Livingston, NJ (Dr Stacey Rifkin-Zenenberg); Saint Christopher's Hospital for Children, Philadelphia, PA (Dr Gregory Halligan); Saint John Hospital and Medical Center, Gross Pointe Woods, MI (Dr Hadi Sawaf); Saint Joseph Children's Hospital of Tampa, Tampa, FL (Dr Hardeo Panchoosingh); Saint Joseph's Regional Medical Center, Peterson, NJ (Dr Mary Bonilla); Saint Jude Children's Research Hospital, Memphis, TN (Dr Wayne Furman); Saint Jude Midwest Affiliate, Peoria, IL (Dr Pedro De Alarcon); Saint Luke's Mountain States Tumor Institute, Boise, ID (Dr Eugenia Chang); Saint Mary's Hospital, West Palm Beach, FL (Dr Narayana Gowda); Saint Peter's University Hospital, New Brunswick, NJ (Dr Stanley Calderwood); Saint Vincent Hospital, Green Bay, WI (Dr John Hill); Saint Vincent Hospital and Health Services, Indianapolis, IN (Dr Bassem Razzouk); San Jorge Children's Hospital, Santurce, PR (Dr Luis Clavell); Sanford Medical Center-Fargo, Fargo, ND (Dr Nathan Kobrinsky); Sanford USD Medical Center - Sioux Falls, Sioux Falls, ND (Dr Kayelyn Wagner); Santa Barbara Cottage Hospital, Santa Barbara, CA (Dr Daniel Greenfield); Scott and White Memorial Hospital, Temple, TX (Dr Guy Grayson); Seattle Children's Hospital, Seattle, WA (Dr Douglas Hawkins); Sinai Hospital of Baltimore, Baltimore, MD (Dr Joseph Wiley); Southern California Permanente Medical Group, Los Angeles, CA (Dr Robert Cooper); Southern Illinois University School of Medicine, Springfield, IL (Dr Gregory Brandt); State University of New York Upstate Medical University, Syracuse, NY (Dr Karol Kerr); Stony Brook University Medical Center, Stony Brook, NY (Dr Robert Parker); T C Thompson Children's Hospital, Chattanooga, TN (Dr Manoo Bhakta); Tampa General Hospital, Tampa, FL (Dr Cameron Tebbi); Texas Tech University Health Science Center-Amarillo (Children' Hospital of San Antonio, San Antonio, TX (Dr Osvaldo Regueira); The Children's Medical Center of Dayton (Dayton Children's Hospital), Dayton, OH (Dr Emmett Broxson); The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, NY (Dr Arlene Redner); The Toledo Hospital/Toledo Children's Hospital, Toledo, OH (Dr Dagmar Stein); The University of Arizona Medical Center-University Campus, Tuscon, AZ (Dr Brenda Wittman); Tripler Army Medical Center, Fort Sam Houston, TX (Dr Della Howell); UMDNJ - Robert Wood Johnson University Hospital (Rutgers Cancer Institute of New Jersey), New Brunswick, NJ (Dr Richard Drachtman); University of Arkansas for Medical Sciences (Arkansas Children's Hospital), Little Rock, AK (Dr David Becton); University of California Davis-Cancer Center, Sacramento, CA (Dr Jay Michael Balagtas); University of California San Francisco Medical Center-Parnassus, San Francisco, CA (Dr Robert Goldsby); University of Chicago, Chicago, IL (Dr Susan Cohn); University of Florida, Gainesville, FL (Dr William Slayton); University of Hawaii, Honolulu, HI (Dr Robert Wilkinson); University of Illinois, Chicago, IL (Dr Mary Schmidt); University of Iowa Hospitals and Clinics, Iowa City, IA (Dr Ayman El-Sheikh); University of Kentucky, Lexington, KY (Dr Martha Greenwood); University of Maryland Greenebaum Cancer Center, Baltimore, ND (Dr Teresa York); University of Massachusetts Medical School, Worcester, MA (Dr Christopher Keuker); University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, FL (Dr Julio Barredo); University of Minnesota Medical Center-Fairview, Minneapolis, MN (Dr Joseph Neglia); University of Mississippi Medical Center, Jackson, MS (Dr Gail Megason); University of Missouri-Columbia (MUHC-Women and Children's Hospital), Columbia, MO (Dr Thomas Loew); University of Nebraska Medical Center, Omaha, NE (Dr Peter Coccia); University of New Mexico, Albuquerque, NM (Dr Koh Boayue); University of North Carolina at Chapel Hill, Chapel Hill, NC (Dr Stuart Gold); University of Oklahoma Health Sciences Center, Oklahoma City OK (Dr Rene McNall-Knapp); University of Rochester, Rochester, NY (Dr Jeffrey Andolina); University of South Alabama, Mobile, AL (Dr Felicia Wilson); University of Texas Health Science Center, San Antonio, TX (Dr Anne-Marie Langevin); University of Texas Southwestern Medical Center, Dallas, TX (Dr Naomi Winick); University of Vermont, Burlington, VT (Dr Alan Homans); University of Virginia, Charlottesville, VA (Dr Kimberly Dunsmore); University of Wisconsin Hospital and Clinics, Madison, WI (Dr Kenneth De Santes); Vanderbilt University, Nashville, TN (Dr Haydar Frangoul); Wake Forest University Health Sciences, Winston-Salem, NC (Dr Thomas McLean); Walter Reed National Military Medical Center, Fort Sam Houston, TX (Dr Della Howell); Washington University School of Medicine, St Louis, MO (Dr Robert Hayashi); Wayne State University, Detroit, MI (Dr Zhihong Wang); Weill Medical College of Cornell University, New York, NY (Dr Alexander Aledo); William Beaumont Hospital (Beaumont Children's Hospital-Royal Oak), Royal Oak, MI (Dr Charles Main); Winthrop University Hospital, Mineola, NY (Dr Mark Weinblatt); Yale University, New Haven, CT (Dr Nina Kadan-Lottick); Covenant Children's Hospital, Lubbock, TX (Dr Latha Prasannan); Dana-Farber Cancer Institute, Boston, MA (Dr Carlos Rodriguez-Galindo); Dartmouth Hitchcock Medical Center, Lebanon, NH (Dr Sara Chaffee); Dell Children's Medical Center of Central Texas, Austin, TX (Dr Sharon Lockhart); Driscoll Children's Hospital, Corpus Christie, TX (Dr M. Cris Johnson); Duke University Medical Center, Durham, NC (Dr Susan Kreissman); East Carolina University, Greeneville, NC (Dr Mauro Grossi); East Tennessee Childrens Hospital, Knoxville, TN (Dr Ray Pais); Eastern Maine Medical Center, Brewer, ME (Dr Sarah Fryberger); Georgia Regents University, Augusta, GA (Dr Colleen McDonough); Hackensack University Medical Center, Hackensack, NJ (Dr Burton Appel); Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, MI (Dr David Dickens); Hurley Medical Center, Flint, MI (Dr Susumu Inoue); Inova Fairfax Hospital, Falls Church, VA (Dr Marshall Schorin); Johns Hopkins University, Baltimore, MD (Dr Kenneth Cohen); Kaiser Permanente-Oakland, Oakland, CA (Dr Steven Bergstrom); Kosair Children's Hospital, Louisville, KY (Dr Salvatore Bertolone); Lehigh Valley Hospital - Muhlenberg, Bethlehem, PA (Dr Philip Monteleone); Loma Linda University Medical Center, Loma Linda, CA (Dr Antranik Bedros); Loyola University Medical Center, Maywood, IL (Dr Ricarchito Manera); Lucile Packard Children's Hospital Stanford University, Palo Alto, CA (Dr Neyssa Marina); M D Anderson Cancer Center, Houston, TX (Dr Najat Daw); Madigan Army Medical Center, Fort Sam Houston, TX (Dr Della Howell); Maine Children's Cancer Program, Scarsborough, ME (Dr Eric Larsen); Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, MD (Dr Crystal Mackall); Marshfield Clinic, Marshfield, WI (Dr Michael McManus); Mary Bridge Children's Hospital and Health Center, Tacoma, WA (Dr Robert Irwin); Massachusetts General Hospital Cancer Center, Boston, MA (Dr Howard Weinstein); Mattel Children's Hospital UCLA, Los Angeles, CA (Dr Pamela Kempert); Mayo Clinic, Rochester, MN (Dr Carola Arndt); Medical City Dallas Hospital, Dallas, TX (Dr Carl Lenarsky); Medical University of South Carolina, Charleston, SC (Dr Jacqueline Kraveka); MedStar Georgetown University Hospital, Washington, DC (Dr Aziza Shad); Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, FL (Dr Iftikhar Hanif); Memorial Sloan Kettering Cancer Center, New York, NY (Dr Peter Steinherz); Memorial University Medical Center, Savannah, GA (Dr J. Martin Johnston); Mercy Children's Hospital, Toledo, OH (Dr Rama Jasty); Mercy Hospital Saint Louis, St Louis, MO (Dr Robin Hanson); Methodist Children's Hospital of South Texas, San Antonio, TX (Dr Jaime Estrada); Miami Children's Hospital, Miami, FL (Dr Enrique Escalon); Michigan State University Clinical Center, East Lansing, MI (Dr Renuka Gera); New York University Langone Medical Center, (Dr Elizabeth Raetz).</p></sec><sec><title>Canada.</title><p>Alberta Children's Hospital, Calgary, AB (Dr Douglas Strother); Allan Blair Cancer Centre, Regina, SK (Dr Mansoor Haq); British Columbia Children's Hospital, Vancouver, BC (Dr Caron Strahlendorf); Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON (Dr Mariana Silva); CancerCare Manitoba, Winnipeg, MB (Dr Rochelle Yanofsky); Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC (Dr Yvan Samson); Children's Hospital, London, ON (Dr Anne Cairney); Children's Hospital of Eastern Ontario, Ottawa, ON (Dr Jacqueline Halton); CHU de Quebec, Quebec, PQ (Dr Bruno Michon); Saskatoon Cancer Centre, Saskatoon, SK (Dr Christopher Mpofu); The Montreal Children's Hospital of the MUHC, Montreal, QC (Dr Sharon Abish); University of Alberta Hospital, Edmonton, AB (Dr Sunil Jayantilal Desai); Hospital for Sick Children, Toronto, ON (Dr Ronald Grant); IWK Health Centre, Halifax, NS (Dr Margaret Yhap); Janeway Child Health Centre, St John's, NF (Dr Lisa Anne Goodyear); McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, ON (Dr Carol Portwine).</p></sec><sec><title>Australia.</title><p>Monash Medical Center-Clayton Campus, Clayton, VIC (Dr Peter Downie); Princess Margaret Hospital for Children, Perth, WA. (Dr Catherine Cole); Royal Children's Hospital, Parkville, VIC (Dr Francoise Mechinaud); Royal Childrens Hospital-Brisbane, Brisbane, QLD (Dr Helen Irving); Sydney Children's Hospital, Randwick, NSW (Dr Draga Barbaric); The Children's Hospital at Westmead, Westmead, NSW (Dr Geoffrey McCowage); Women's and Children's Hospital-Adelaide, North Adelaide, SA (Dr Maria Kirby).</p></sec><sec><title>Switzerland.</title><p>Swiss Pediatric Oncology Group - Bern, Bern (Dr Roland Ammann); Swiss Pediatric Oncology Group - Geneva, Geneva (Dr Marc Ansari); Swiss Pediatric Oncology Group - Lausanne, Lausanne (Dr Maja Beck Popovic).</p></sec><sec><title>New Zealand.</title><p>Christchurch Hospital, Christchurch (Dr Michael Sullivan); Starship Children's Hospital, Auckland (Dr Teague).</p></sec><sec><title>Mexico.</title><p>Hospital Infantil de Mexico Federico Gomez, Mexico City (Dr Aurora Medina-Sanson).</p></sec></sec><sec><title>COG Panel Representatives and Additional Contributors</title><p>Neyssa Marina, Chief Investigator; TMG Member: Chief Investigator; National Coordinator; Oncology Panel</p><p>Mark Bernstein, Chief Investigator; TMG Chair; National Coordinator; Oncology Panel</p><p>Caroline Wang, TMG Member: Research Coordinator</p><p>Justin Davis, TMG Member: Research Coordinator</p><p>Possidonia Gontijo, TMG Member: Research Coordinator</p><p>Mark Krailo, TMG Member: Statistician</p><p><bold>Statistics Panel:</bold></p><p>Allen Goorin, Oncology Panel</p><p>Paul Meyers, Oncology Panel</p><p>Lisa Teot,* Pathology Review Panel</p><p>Richard Gorlick,* Biological Studies Panel</p><p>Chand Khanna, Biological Studies Panel</p><p>Ching Lau, Biological Studies Panel</p><p>Doug Letson,* Surgical Panel</p><p>Mark Gebhardt, Surgical Panel</p><p>Lor Randall, Surgical Panel</p><p>James Meyer, Radiology Panel</p><p>Helen Nadel, Radiology Panel</p><p>Paula Schomberg, Radiotherapy Panel</p><p>Amy Barr, Pharmacy Panel</p><p>(*) Group representative</p></sec><sec><title>A2. Cooperative Osteosarkom Studiengruppe (COSS)</title><sec><title>Austria.</title><p>(Univers) Kinderklinik, Graz (Herrn Univ. Prof. Dr C. Urban); Univers. Kinderklinik, Innsbruck (Herrn Prof. Dr B. Meister); LKA Salzburg, Salzburg (Herrn OA Dr N. Jones).</p></sec><sec><title>Czech Republic.</title><p>Univ. Childrens Hosp. Brno, Brno (Herrn Prof. Dr P. Mudry); University Hospital MOTOL, Prag (Herrn Dr med. H. Mottl).</p></sec><sec><title>Germany.</title><p>Universit&#x000e4;tskinderklinik, Aachen (Herrn Prof. Dr R. Mertens); Krh. -Zweckverband Augsburg, Augsburg (Frau O&#x000c4; Dr A. K. Gnekow); Zentralklinikum, Augsburg (Herrn Prof. Dr G. Schlimok); Helios Kliniken Bad Saarow, Bad Saarow (Herrn PD Dr med. Reichardt); Sozialstiftung Bamberg, Klinikum am Bruderwald, Bamberg (Herrn Priv.-Doz. Dr med. Roland Repp); Klinikum Bayreuth, Bayreuth (Herrn Prof. Dr Th. Rupprecht); Charit&#x000e9; Campus Virchow Klinikum Berlin, Berlin (Frau Prof. Dr med. A. Eggert); Ev. Waldkrankenhaus Spandau, Berlin (Herrn Dr Potenberg); Ev. Waldkrankenhaus Spandau, Berlin (Herrn Prof. Dr Noack); Helios Klinikum Berlin - Buch, Berlin (Herrn PD Dr med. Reichardt); Helios Klinikum Berlin-Buch; Klinik f&#x000fc;r Kinder und Jugendmedizin, Berlin (Herrn Prof. Dr L. Schweigerer); Charite, Berlin (Herrn Dr Jan Eucker); Charite - Campus Virchow Klinikum, Berlin (Herrn OA Dr P. Thuss-Patience); Ev. Krankenhaus Bielefeld gGmbH, Bielefeld (Herrn OA Dr Jorch); Ev. Krankenhaus, Bielefeld (Herrn PD Dr med. F. Wei&#x000df;inger); Univers. Kinderklinik, Bonn (Herrn Dr med. Stefan Sch&#x000f6;nberger); St&#x000e4;dt. Klinikum Holwedestra&#x000df;e, Braunschweig (Herrn OA Dr med. Eberl); Klinikum Bremen - Mitte gGmbh / Prof.-Hess-Kinderklinik, Bremen (Herrn Prof. Dr Pekrun); Klinikum Bremen-Mitte, Bremen (Frau Dr med. Henrike Thomssen); Ev. Diakonie-Krankenhaus, Bremen (Herrn Prof. Dr Pfl&#x000fc;ger); Klinikum Chemnitz, Chemnitz (Herrn OA Dr med. A. Hofmann); Klinikum Chemnitz gGmbH, Chemnitz (Herrn PD Dr med. M. H&#x000e4;nel); Kliniken Dortmund, Dortmund (Frau Dr S. B&#x000e4;umer); St&#x000e4;dt. Kliniken, Dortmund (Herrn Prof. Dr med. Schneider); Univers. Kinderklinik, Dresden (Herrn Prof. Dr med. M. Suttorp); Med. Universit&#x000e4;tsklinik I, Dresden (Herrn PD Dr G. Folprecht); Univers. Kinderklinik, D&#x000fc;sseldorf (Herrn Prof. Dr Borkhardt); Med. Universit&#x000e4;tsklinik &#x00026; Poliklinik, D&#x000fc;sseldorf (Herrn Prof. Dr R. Haas); Helios Klinikum Erfurt, Erfurt (Herrn CA PD Dr Sauerbrey); Universit&#x000e4;tsklinikum Erlangen Kinder- und Jugendklinik, Erlangen (Herrn PD Dr med. Markus Metzler); Universit&#x000e4;tsklinikum Erlangen, Erlangen (Herrn PD Dr med. Spriewald); Waldkrankenhaus St. Marien, Erlangen (Herrn PD Dr med. G. Preclik); Univers. Kinderklinik, Essen (Prof. Dr Bernhard Kremens); Univers. Kinderklinik, Frankfurt (Herrn Prof. Dr Klingebiel); Universit&#x000e4;tsklinik, Frankfurt (Herrn Prof. Dr Bergmann); Universit&#x000e4;tsklinikum Freiburg Zentrum f&#x000fc;r Kinder- und Jugendmedizin, Freiburg (Frau Prof. Dr med. Charlotte Niemeyer); Klinik Sanafontis, Freiburg (Herrn Dr med. J. Rentschler); Klinik Sanafontis, Freiburg (Herrn PD Dr med. J. Drevs); Univers. Kinderklinik, Gie&#x000df;en (Herrn Prof. Dr Reiter); Univ. Klinikum Gie&#x000df;en, Gie&#x000df;en (Herrn Prof. Dr med. M. Rummel); Universit&#x000e4;tskinderklinik G&#x000f6;ttingen, G&#x000f6;ttingen (Herrn Prof. Dr med. Lakomek); Medizinische Klinik &#x00026; Poliklinik, G&#x000f6;ttingen (Herrn Prof. Dr L. Tr&#x000fc;mper); Univ. Klinikum Greifswald, Greifswald (Herrn Prof. Dr med. H. Lode); Universit&#x000e4;tsmedizin Greifswald, Greifswald (Herrn Dr Christian-Andreas Schmidt); Krankenhaus St. Elisabeth / St. Barbara, Halle (Frau O&#x000c4; Dr G. G&#x000fc;nther); Med. Universit&#x000e4;tsklinik / Innere IV, Halle (Herrn Dr med. H.-H.- Wolf); Universit&#x000e4;tsklinik f. Kinder &#x00026; Jugendmedizin, Halle / Saale (Herrn Prof. Dr K&#x000f6;rholz); Univers. Kinderklinik, Hamburg (Herrn Dr med. Hassenpflug); Med. Hochschule Hannover, Hannover (Herrn Prof. Dr A. Beilken); MHH Zentrum Innere Medizin, Hannover (Herrn Prof. Dr med. Christoph Reuter); Klinikum Siloah, Hannover (Herrn PD Dr Kirchner); Univers. Klinik f. Kinder &#x00026; Jugendmedizin, Heidelberg (Herrn OA Dr med. Wolfgang Behnisch); Med. Klinik &#x00026; Poliklinik V, Heidelberg (Frau O&#x000c4; Prof. Dr Egerer); Orthop. Universit&#x000e4;tsklinik I, Heidelberg (Herrn Prof. Dr Ewerbeck); SLK Kliniken Heilbronn, Heilbronn (Frau Dr M. Streiter); Gemeinschaftskrankenhaus Herdecke, Herdecke (Herrn Dr med. A. L&#x000e4;ngler); Univers. Kinderklinik, Homburg (Herrn Prof. Dr Graf); Med. Universit&#x000e4;tsklinik I, Homburg (Herrn Prof. Dr Pfreundschuh); Univers. Kinderklinik, Jena (Herrn OA. Dr med. Gruhn); Universit&#x000e4;tsklinikum Jena, Jena (Herrn Dr med. Schmalenberg); St&#x000e4;dt. Klinikum Karlsruhe, Karlsruhe (Herrn Dr med. A. Leipold); Klinikum Kassel, Kassel (Frau PD Dr med. Nathrath); Universit&#x000e4;tsklinikum Schleswig - Holstein, Kiel (Herrn Prof. Dr M. Schrappe); Universit&#x000e4;tsklinikum Schleswig-Holstein, Kiel (Herrn Prof. Dr Kneba); Gemeinschaftsklinikum Kemperhof Koblenz, Koblenz (Herrn OA Dr Ferrari); Uniklinik K&#x000f6;ln, K&#x000f6;ln (Herrn Prof. Dr med. T. Simon); Med. Universit&#x000e4;tsklinik I, K&#x000f6;ln (Herrn Prof. J-M. Chemnitz); Helioskliniken Krefeld, Krefeld (Herrn Thomas Imschweiler); Univers. Kinderklinik Leipzig, Leipzig (Herrn Prof. Dr med. Christiansen); Universit&#x000e4;tsklinikum Leipzig, Leipzig (Herrn Prof. Dr med. Dr h. c. Niederwieser); Landes- Frauen- und Kinderklinik Linz, Linz (Herrn Prof. Dr K. Schmitt); Univers. Kinderklinik, L&#x000fc;beck (Herrn PD Dr med. M. Lauten); Klinikum L&#x000fc;denscheid, L&#x000fc;denscheid (Herrn Prof. Dr med. G. Heil); Klinikum d. Stadt Ludwigshafen, Ludwigshafen (Herrn Prof. Dr Uppenkamp); St. Marien u. St. Annastiftskrankenhaus Ludwigshafen/Rh, Ludwigshafen (Abteilung aufgel&#x000f6;st); Universit&#x000e4;tsklinikum Magdeburg A.&#x000f6;.R Universit&#x000e4;tskinderklinik, Magdeburg (Herrn Prof. Dr med. Vorwerk); Med. Universit&#x000e4;tsklinik III, Mainz (Herrn OA Dr H. J. Beck); Univers. Kinderklinik Mainz, Mainz (Herrn PD Dr J&#x000f6;rg Faber); Universit&#x000e4;tskinderklinik Mannheim, Mannheim (Herrn PD Dr D&#x000fc;rken); Univers. Kinderklinik, Marburg (Frau Dr med. Barbara Sch&#x000fc;tz); Johannes Wesling Klinikum Minden, Minden (Herrn PD Dr Erdlenbruch); Kinderklinik &#x00026; Poliklinik d. TU M&#x000fc;nchen, M&#x000fc;nchen (Frau PD Dr med. Irene Teichert von L&#x000fc;ttichau); III. Medizinische Klinik &#x00026; Poliklinik re. d. Isar, M&#x000fc;nchen (Herrn PD Dr I. Ringshausen); Dr von Haunersches Kinderspital, M&#x000fc;nchen (Frau O&#x000c4; PD Dr med. I. Schmid); Klinikum Gro&#x000df;hadern, M&#x000fc;nchen (Herrn PD Dr Lars Lindner); Medizinische Klinik &#x00026; Poliklinik, M&#x000fc;nster (Herrn Prof. Dr Berdel); Universit&#x000e4;tsklinikum M&#x000fc;nster, M&#x000fc;nster (Herrn Prof. Dr J&#x000fc;rgens); Cnopf&#x000b4;sche Kinderklinik, N&#x000fc;rnberg (Herrn Prof Dr Scheurlen); Med. Universit&#x000e4;tsklinik V, N&#x000fc;rnberg (Herrn Prof. Dr M. Wilhelm); Pius-Hospital, Oldenburg (Herrn Prof. Dr F. Griesinger); Klinikum Oldenburg gGmbH, Oldenburg (Herr Prof. Dr M&#x000fc;ller); Br&#x000fc;derkrankenhaus St. Josef Paderborn, Paderborn (Herrn CA Dr med. T. Gaska); Klinikum Passau, Passau (Herrn CA PD Dr T. S&#x000fc;dhoff); Krhs. Barmherzige Br&#x000fc;der, Regensburg (Herrn Prof. Dr med. Jan Braess); Med. Universit&#x000e4;tsklinik, Regensburg (Frau Dr med. Ch. Hart); Univ. Kinderklinik Regensburg, Regensburg (Herrn Prof. Dr med. Corbacioglu); Universit&#x000e4;tsklinikum Rostock, Rostock (Herrn PD Dr med. C. F. Classen); Diakoniekrankenhaus Rotenburg, Rotenburg (Herrn Dr med. F. Heits); Klinikum Saarbr&#x000fc;cken, Saarbr&#x000fc;cken (Herrn Dr Joachim Weis); Diakonie - Klinikum, Schw&#x000e4;bisch Hall (Herrn Dr Thomas Geer); Helios Kliniken Schwerin, Schwerin (Herrn OA Dr med. Kasbohm); Heliosklinikum Schwerin, Schwerin (Herrn Dr D. H&#x000e4;hling); Asklepios Klinik St. Augustin, St. Augustin (Herrn Dr med. Harald Reinhard); Klinikum Stuttgart; Zentrum f&#x000fc;r Kinder- und Jugendmedizin - Olgahospital, Stuttgart (Herrn Prof. Dr Bielack); Diakonie-Klinikum-Stuttgart, Stuttgart (Frau Prof. Dr Heidemann); Marienhospital, Stuttgart (Herrn Prof. Dr med. Denzlinger); Klinikum Stuttgart/Krh. Bad Cannstatt, Stuttgart (Herrn Prof. Dr med. Andus); Univers. Kinderklinik, T&#x000fc;bingen (Herrn Prof. Dr med. Rupert Handgretinger); Univers. Kinderklinik &#x00026; Poliklinik, Ulm (Herrn Prof. Dr Debatin).</p></sec><sec><title>Hungary.</title><p>&#x000c1;llami Eg&#x000e9;szs&#x000e9;g&#x000fc;gyi K&#x000f6;zpont, Budapest (Frau Dr Zsuzsanna P&#x000e1;pai); SE Orthop&#x000e4;dische Klinik, Budapest (Herrn Prof. Dr M. Szendroi); II. Kinderklinik der Semmelweis Universit&#x000e4;t, Budapest (Herrn Dr Gabor Kovacs).</p></sec><sec><title>Switzerland.</title><p>Kantonspital Aarau, Aarau (Frau O&#x000c4; Dr Angst); Universit&#x000e4;ts-Kinderspital beider Basel, Basel (Herrn Prof. Dr med. Thomas K&#x000fc;hne); Ospedale San Giovanni, Bellinzona (Herrn Dr P. Brazzola); Kantonsspital Luzern, Luzern 16 (Herrn PD Dr Rischewski).</p></sec></sec><sec><title>COSS Panel Representatives and Additional Contributors</title><p>Stefan Bielack, Chief Investigator; TMG Member: Chief Investigator; National Coordinator: Germany, Oncology Panel: Paediatric Oncology</p><p>Beate Kempf-Bielack, TMG Member: Study Physician</p><p>Miriam Wilhelm, TMG Member: Study Physician</p><p>Katja Zils, TMG Member: Study Physician</p><p>Joachim Gerss, TMG Member: Statistician</p><p>Matthias Kevric, TMG Member: Data Manager</p><p>Benjamin Sorg, TMG Member: Data Manager</p><p>Dorothe Carrle, TMG Member: Study Physician</p><p>Feven Assefaw: Secretary</p><p>Lynn Hazlewood: Secretary</p><p>Claudia Wurster: Secretary</p><p>Leo Kager, National Coordinator: Austria; Oncology Panel: Paediatric Oncology</p><p>Zsuzsanna P&#x000e1;pai, National Coordinator: Hungary</p><p>Thomas K&#x000fc;hne, National Coordinator: Switzerland</p><p>Hubert Mottl, National Coordinator: Czech Republic</p><p>Thomas K&#x000fc;hne, Oncology Panel: Paediatric Oncology</p><p>Peter Reichardt, Oncology Panel: Medical Oncology</p><p>Zsuzsanna P&#x000e1;pai, Oncology Panel: Medical Oncology</p><p>Udo Kontnyl, Oncology Panel: Paediatric Oncology</p><p>W. Hassenpflug, Oncology Panel: Paediatric Oncology</p><p>Norbert Graf, Oncology Panel: Paediatric Oncology</p><p>Michaela Nathrath, Oncology Panel: Paediatric Oncology; Biological Studies Panel</p><p>Wolfgang E. Berdel, Oncology Panel: Medical oncology</p><p>Heribert J&#x000fc;rgens, Oncology Panel: Paediatric Oncology</p><p>Regine Meyer-Steinacker, Oncology Panel: Medical Oncology</p><p>Gernot Jundt,* Pathology Review Panel</p><p>Andreas Schulz, Pathology Review Panel</p><p>G&#x000fc;nter Delling, Pathology Review Panel</p><p>Mathias Werner, Pathology Review Panel</p><p>Albert Roessner, Pathology Review Panel</p><p>Gabriele K&#x000f6;hler (<italic>associate</italic>: Ch. Dierkes), Pathology Review Panel</p><p>Horst B&#x000fc;rger, Pathology Review Panel</p><p>Susanna Lang (<italic>associate</italic>: Irene Sulzbacher), Pathology Review Panel</p><p>Arthur R. von Hochstetter, Pathology Review Panel</p><p>Gabriela Arato, Pathology Review Panel</p><p>Gernot Jundt,* Biological Studies Panel</p><p>W. Hassenpflug, Biological Studies Panel</p><p>Rainhard Windhager* (<italic>associate</italic>: Martin Dominkus), Surgical Panel</p><p>Per-Ulf Tunn, Surgical Panel</p><p>Miklos Szendroi (<italic>associate</italic>:. Imre Antal), Surgical Panel</p><p>Detlev Branscheid, Surgical Panel: Thoracic Surgery Representative</p><p>Godehard Friedel, Surgical Panel: Thoracic Surgery Representative</p><p>Ulrich Heise, Surgical Panel</p><p>Volker Ewerbeck, Surgical Panel</p><p>H. Roland D&#x000fc;rr, Surgical Panel</p><p>Axel Hillmann, Surgical Panel</p><p>Georg Gosheger (<italic>associate</italic>: Jendrik Hardes), Surgical Panel</p><p>G. Ulrich Exner, Surgical Panel</p><p>Joachim Sciuk, Radiology Panel: Nuclear Medicine</p><p>Knut Helmke, Radiology Panel: Diagnostic Radiology</p><p>Peter Winkler (<italic>associate: Thekla v. Kalle</italic>), Radiology Panel: Diagnostic Radiology</p><p>Reiner Maas, Radiology Panel: Diagnostic Radiology</p><p>Christiane Franzius, Radiology Panel: Nuclear Medicine</p><p>Joachim Gerss, Statistics Panel</p><p>Rudolf Schwarz, Radiotherapy Panel</p><p>Beate Timmermann, Radiotherapy Panel: Particle Therapy</p><p>Elvira Ahlke &#x00026; Hedwig Kolve, Pharmacy Panel</p><p>(*) Group representative</p></sec><sec><title>A3. European Osteosarcoma Intergroup (EOI)</title><sec><title>United Kingdom.</title><p>University College Hospital, London (Prof. Jeremy Whelan); Royal Hospital for Sick Children, Edinburgh (Dr Hamish Wallace); Birmingham Childrens Hospital, Birmingham (Dr Bruce Morland); Sheffield Children's Hospital, Sheffield (Dr Vicki Lee, Dr Mary Gerrard); Christie Hospital, Manchester (Dr Bernadette Brennan); Royal Manchester Children's Hospital, Manchester (Dr Bernadette Brennan); Addenbrooke's Hospital, Cambridge (Dr Amos Burke); Royal Marsden Hospital, London (Dr Julia Chisholm, Prof. Kathy Pritchard-Jones); Royal Hospital for Sick Children, Glasgow (Dr Milind Ronghe); Beatson West of Scotland Cancer Centre, Glasgow (Dr Jeff White); Royal Aberdeen Childrens Hospital, Aberdeen (Dr Derek King); Queens Medical Centre, Nottingham (Prof. David Walker); St James University Hospital, Leeds (Dr Susan Picton, Dr Ian Lewis); Children's Hospital for Wales, Cardiff (Dr Heidi Traunecker); Royal Orthopaedic Hospital, Birmingham (Dr David Peake); Royal Victoria Infirmary, Newcastle (Dr Juliet Hale); Nottingham University Hospitals, City Campus, Nottingham (Dr Ivo Hennig, Dr Michael Sokal); Southampton General Hospital, Southampton (Dr Gary Nicolin); Bristol Royal Hospital for Children, Bristol (Prof. Mike Stevens); Ninewells Hospital, Dundee (Dr Michelle Ferguson, Prof. Elaine Rankin); Weston Park Hospital, Sheffield (Prof. Penella Woll); Leicester Royal Infirmary, Leicester (Dr Johannes Visser); Clatterbridge Centre for Oncology, Liverpool (Dr Peter Clark, Dr Nasim Ali); Churchill Hospital, Oxford (Prof. Bass Hassan); Royal Liverpool Childrens Hospital, Liverpool (Dr Barry Pizer, Dr Heather McDowell); Bristol Haematology &#x00026; Oncology Centre, Bristol (Prof. Mike Stevens); Newcastle General Hospital, Newcastle (Dr Mark Verrill).</p></sec><sec><title>Netherlands.</title><p>Leiden University Medical Center, Leiden (Prof. Hans Gelderblom, Dr Jacob Anninga); Emma's Children's Hospital/AMC Amsterdam, Amsterdam (Dr Henk Van Den Berg); Radboud University Nijmegen Medical Centre, Nijmegan (Prof. Hoogerbrugge); University Medical Center Groningen, Groningen (Prof. WA Kamps, Dr ESJM De Bont).</p></sec><sec><title>Belgium.</title><p>University Hospital Ghent, Ghent (Dr Catharina Dhooge); UZ Brussels, Brussels (Dr An Van Damme, Dr Jutte Van der Werff ten Bosch); Jules Bordet Institute, Brussels (Dr Thierry Gil); Universitaire Ziekenhuizen Leuven, Leuven (Dr Marleen Renard); Cliniques Universitaires Saint-Luc, Brussels (Prof. Benedicte Brichard); Hopital Universitaire des Enfants, Brussels (Dr Sophie Huybrechts).</p></sec><sec><title>Ireland.</title><p>Our Lady's Children's Hospital, Dublin (Dr Michael Capra).</p></sec></sec><sec><title>EOI Panel Representatives and Additional Contributors</title><p>Jeremy Whelan, Chief Investigator; National Coordinator: United Kingdom; Oncology Panel ; TMG Member: Chief Investigator</p><p>Nicola Joffe, TMG Member; Clinical Project Manager</p><p>Sue Fleck, TMG Member; Clinical Project Manager</p><p>Karen Sanders, TMG Member; Clinical Project Manager; Data Manager</p><p>Barbara Uscinska, TMG Member; Clinical Project Manager</p><p>James Pickering, TMG Member; Trial Manager; Data Manager</p><p>Gintare Rutkauskaite. TMG Member; Trial Manager</p><p>Aurelie Faysse, TMG Member; Trial Manager</p><p>Sarah Beall, TMG Member; Trial Manager</p><p>Beth May, TMG Member; Trial Manager</p><p>Anne Holliday, TMG Member; Trial Manager</p><p>Monica Tomiczek, TMG Member; Trial Manager, Data Manager</p><p>Matthew Sydes, TMG Member; Trial Statistician; Statistics Panel</p><p>Gordana Jovic, TMG Member; Statistician</p><p>Jane Hook, TMG Member; Study Physician</p><p>Leonardo Trani, TMG Member; Study Physician</p><p>Martha Perisoglou, TMG Member; Study Physician</p><p>Catharina Dhooge (Claeys), National Coordinator: Belgium</p><p>Rachel Jinks, TMG Member; Statistician</p><p><bold>Oncology Panel:</bold></p><p>Michael Capra, National Coordinator: Ireland</p><p>Jakob Anninga, National Coordinator: Netherlands, Oncology Panel</p><p>Hans Gelderblom, National Coordinator: Netherlands</p><p>Bruce Morland, Oncology Panel</p><p>Ian Lewis, Oncology Panel</p><p>Pancras Hogendoorn,* Pathology Review Panel; Biological Studies Panel</p><p>Judith V.M.G. Bovee, Pathology Review Panel</p><p>J. Bras, Pathology Review Panel</p><p>Adrienne Flanagan, Pathology Review Panel</p><p>Elaine MacDuff, Pathology Review Panel</p><p>Robin Reid, Pathology Review Panel</p><p>Petra Dildey, Pathology Review Panel</p><p>David E Hughes, Pathology Review Panel</p><p>Esther Hauben, Pathology Review Panel</p><p>Chas Mangham, Pathology Review Panel</p><p>Anne Marie Cleton Jansen, Biological Studies Panel</p><p>Rob Grimer,* Surgical Panel</p><p>Steve Cannon, Surgical Panel</p><p>Anthony Taminiau, Surgical Panel</p><p>Michael Gebhart, Surgical Panel</p><p>Mark Davies, Radiology Panel</p><p>Paul O'Donnell, Radiology Panel</p><p>William Ramsden, Radiology Panel</p><p>H.J. van der Woude, Radiology Panel</p><p>Koenraad Verstraete, Radiology Panel</p><p>Anna Cassoni, Radiotherapy Panel</p><p>Denise Blake, Pharmacy Panel</p><p>(*) Group representative</p></sec><sec><title>A4. Scandinavian Sarcoma Group (SSG)</title><sec><title>Norway.</title><p>Oslo University Hospital (Dr Kirsten Sundby Hall); Bergen University Hospital (Dr Odd Monge); Trondheim University Hospital (Dr Erling Moe).</p></sec><sec><title>Sweden.</title><p>Ume&#x000e5; University Hospital (Dr Ulf Hjalmars (Children)Dr Beatrice Malmer, Dr Kjell Johansson (Children)); Link&#x000f6;ping University Hospital (Dr Najme Wall, Dr Maria &#x000d6;stlund, Dr Mikael Behrendtz); Gothenburg Sahlgrenska University Hospital (Dr Lina Hansson, Dr Gustaf &#x000d6;sterlundh (Children), Dr Monika Sender, Dr Katarina Engstr&#x000f6;m,); Lund University Hospital, Oncologic dept. (Dr Mikael Eriksson, Dr Lars Hjorth (Children)); Akademiska sjukhuset, Uppsala University Hospital (Dr Ingela Turesson, Dr Gustaf Ljungman (Children)); Karolinska University Hospital, Stockholm (Dr Elisabet Lidbrink, Dr Cecilia Petersen (Children), Dr Mikael Szeps, Dr Annika Folin, Dr Christina Linder-Stragliotto, Dr Jonas Karl&#x000e9;n (Children), Dr &#x000c5;ke Jacobson (Children)).</p></sec><sec><title>Finland.</title><p>Tampere University Hospital (Dr Tuula Lehtinen); Helsinki University Central Hospital (Dr Maija Tarkkanen); Turku University Hospital (Dr Paula Lindholm).</p></sec><sec><title>Denmark.</title><p>Aarhus University Hospital (Dr Akmal Safwat (Adult), Dr Ole Steen Nielsen, Dr Henrik Hasle (Children)); Copenhagen Rigshospital (Dr Catherine Rechnitzer).</p></sec></sec><sec><title>SSG Panel Representatives and Additional Contributors</title><p>Sigbj&#x000f8;rn Smeland, Chief Investigator; TMG Member: Chief Investigator; National Coordinator: Norway Oncology Panel</p><p>Maria Rejmyr-Davis, TMG Member: Data Manager</p><p>Eva-Mari Olofsson, TMG Member: Research Administrator</p><p>Elisabeth Johansson, TMG Member: Data Manager</p><p>Linda Werner-Hartman, TMG Member: Statistician</p><p>Thor Alveg&#x000e5;rd, TMG Member: Data Manager Supervisor</p><p>Ole Sten Nielsen, National Coordinator: Denmark</p><p>Maija Tarkkanen, National Coordinator: Finland</p><p>Oskar Johansson, National Coordinator: Iceland</p><p>Mikael Eriksson, National Coordinator: Sweden</p><p>Oskar Hagberg, Statistician</p><p>Karolina Carlsson, Statistician</p><p>Viktoria Samuelsson, Statistician</p><p>Anna Bladtr&#x000f6;m, Statistician</p><p>Jeanette Ceberg, Monitor</p><p>Christina Danewid, Monitor</p><p>Mercedes Marotta, Data Systems Engineer</p><p>Mona Malstr&#x000f6;m, CRF Designer</p><p><bold>Oncology Panel:</bold></p><p>Thomas Wiebe, Oncology Panel</p><p>&#x000c5;ke Jakobson, Oncology Panel</p><p>Maija Tarkkanen, Oncology Panel</p><p>Ole Steen Nielson, Oncology Panel</p><p>Tom B&#x000f6;hling,* Pathology Review Panel</p><p>Lars-Gunnar Kindblom,* Pathology Review Panel</p><p>Henryk Domanski, Pathology Review Panel</p><p>Bodil Bjerkehagen, Pathology Review Panel</p><p>Johan Wejde, Pathology Review Panel</p><p>Ola Myklebost, Biological Studies Panel</p><p>Nils Mandahl, Biological Studies Panel</p><p>Sakari Knuutila, Biological Studies Panel</p><p>Otte Brosj&#x000f6;, Surgical Panel</p><p>Ingeborg Taksdal,* Radiology Panel</p><p>Veli S&#x000f6;derlund, Radiology Panel</p><p>&#x000d8;yvind Bruland, Radiotherapy Panel</p><p>Linda Werner-Hartman, Statistics Panel</p><p>Tor Sk&#x000e4;rby, Pharmacy Panel</p><p>(*) Group representative</p></sec><sec><title>A5. Members of Independent Oversight Committees</title><p><bold>Independent Data Monitoring Committee:</bold></p><p>Barry Hancock, Chair: Sheffield, United Kingdom</p><p>Gerald Gilchrist, Member: Minnesota, United States</p><p>Otilia Dalesio, Member: Amsterdam, the Netherlands</p><p>Peter H&#x000f8;glund, Member: Lund, Sweden</p><p><bold>Trial Steering Committee:</bold></p><p>Stefano Ferrari, Chair: Bologna, Italy</p><p>Joseph Mirro, Member: Memphis, United States</p><p>Hans Strander, Member: Stockholm, Sweden</p><p>Robert Souhami, Member: London, United Kingdom</p></sec><sec><title>A6. Members of EURAMOS Intergroup Safety Desk (EISD)</title><p>Trude Butterfa&#x000df;-Bahloul, TMG Member: Clinical Research Associate SAE, Safety Desk Manager</p><p>Heidi Oellers, TMG Member: Monitoring/Auditing</p><p>Marc Urban, TMG Member: Monitoring/Auditing</p><p>Karl-Friedrich Lukat, Clinical Research Associate SAE, Safety Desk Manager</p><p>Melanie Langeleist: Safety Desk Assistant</p><p>Dorothe H&#x000fc;lser: Safety Desk Assistant</p><p>Gudrun W&#x000fc;rthwein: Data Management of Safety Database</p><p>Sonja Baier: Data Management of Safety Database</p><p>Attyla Drabik: Safety Desk Manager</p><p>Charlotte Young: Safety Desk Manager</p><p>Kirsten Werner: Safety Desk Manager</p><p>Andrea Paneitz: Safety Desk Manager</p><p>Ruth Wagner: Safety Desk Manager</p><p>Eva Gr&#x000fc;newald: Safety Desk Manager</p><p>Christiana Rohde-Osei: Safety Desk Assisant</p><p>Kerstin Hovestadt: Safety Desk Assistant</p><p>Linus Lauterbach: Safety Desk Assistant</p></sec><sec><title>B7. Members of Quality of Life Coordinating Centre</title><p>Gabriele Calaminus, TMG Member: Quality of Life Panel</p><p>Andreas Wiener, TMG Member: Quality of Life Panel</p><p>Katja Baust: Psychotherapist</p><p>Carmen Teske: Study Documentation</p><p>Karina Riemenschneider: Secretary</p></sec></sec></app></app-group></back></article>